ID=H0016
URL=http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/Mellors.html
SIZE=202362
DATE=11/07/2002
TIME=17:00:06
DATASET=Biology
HTML=  
<html>
  <head>
    <title></title>
      <style type="text/css">
	<!--
	  span.red {color: red}
	  span.green {color: green}
          span.small {size:"-1"}
	  input.lavender {background: lavender;
			  color: green}
	  ul.tip {list-style-type: none} 
	  .a11 {color: black; 
                font-size: 11pt; 
                font-weight: normal; 
                text-decoration: none; 
                font-family: Arial, Helvetica, sans-serif}
          a:link {color: blue; 
                  text-decoration : none; 
                  font-weight: normal}
	  a:visited {color : blue;
                     text-decoration : none;
                     font-weight : normal}
          a:hover {color: brown; 
                   text-decoration : none; 
                   font-weight: normal}
#pup {position:absolute; visibility:hidden; z-index:200; width:130; }
//-->
      </style>	
  </head>
  <body bgcolor="white">
    <table bgcolor="white" width="100%" border=0 cellspacing=0 cellpadding=3>
      <tr valign="top">
	<td width="10%" bgcolor="#eaeaea">
               <!--
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>

<HEAD>
  <TITLE>
    HIV sequence database navigation frame
  </TITLE>
</HEAD>


<BODY> 
	BACKGROUND="" 
	BGCOLOR="#eaeaea" 
	TEXT="#000000" 
	LINK="#0000ff" 
	VLINK="#800080" 
	ALINK="#ff0000"
-->

<A HREF="/content/hiv-db/mainpage.html">
	
<IMG SRC="/content/hiv-db/IMAGES/VirusTransparent.gif" BORDER=0></A>

<P>
<CENTER>
</CENTER>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerDatabases.gif" BORDER=0></A><BR>

<A HREF="/content/hiv-db/mainpage.html" 
	onMouseOver="document.Sequence.src='/content/hiv-db/NAVIFRAME/YELLOW/_SequenceDB.gif' "
	onMouseOut="document.Sequence.src='/content/hiv-db/NAVIFRAME/YELLOW/SequenceDB.gif' " >
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SequenceDB.gif" BORDER=0 NAME="Sequence"></A><BR>

<A HREF="http://resdb.lanl.gov/Resist_DB/default.htm" 
	onMouseOver="document.Resistance.src='/content/hiv-db/NAVIFRAME/YELLOW/_ResistanceDB.gif' "
	onMouseOut="document.Resistance.src='/content/hiv-db/NAVIFRAME/YELLOW/ResistanceDB.gif'">
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/ResistanceDB.gif" BORDER=0 NAME="Resistance"></A><BR>

<A HREF="/content/immunology/index" 
	onMouseOver="document.Immunology.src='/content/hiv-db/NAVIFRAME/YELLOW/_ImmunologyDB.gif' "
	onMouseOut="document.Immunology.src='/content/hiv-db/NAVIFRAME/YELLOW/ImmunologyDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/ImmunologyDB.gif" BORDER=0 NAME="Immunology"></A><BR>

<A HREF="/content/vaccine/html/index.html" 
	onMouseOver="document.VaccineTrials.src='/content/hiv-db/NAVIFRAME/YELLOW/_VaccinetrialsDB.gif' "
	onMouseOut="document.VaccineTrials.src='/content/hiv-db/NAVIFRAME/YELLOW/VaccinetrialsDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/VaccinetrialsDB.gif" BORDER=0 NAME="VaccineTrials"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<P>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerPublications.gif" BORDER=0></A><BR>

<A HREF="/content/hiv-db/HTML/FAQ.html" 
	onMouseOver="document.Faq.src='/content/hiv-db/NAVIFRAME/YELLOW/_FAQ.gif' "
	onMouseOut="document.Faq.src='/content/hiv-db/NAVIFRAME/YELLOW/FAQ.gif' ">
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/FAQ.gif" BORDER=0 NAME="Faq"></A><BR>

<A HREF="/content/hiv-db/ALIGN_CURRENT/ALIGN-INDEX.html" 
	onMouseOver="document.Alignments.src='/content/hiv-db/NAVIFRAME/YELLOW/_Alignments.gif' "
	onMouseOut="document.Alignments.src='/content/hiv-db/NAVIFRAME/YELLOW/Alignments.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Alignments.gif" BORDER=0 NAME="Alignments"></A><BR>

<A HREF="/content/hiv-db/HTML/Tutorials.html" 
	onMouseOver="document.Tutorials.src='/content/hiv-db/NAVIFRAME/YELLOW/_Tutorials.gif' "
	onMouseOut="document.Tutorials.src='/content/hiv-db/NAVIFRAME/YELLOW/Tutorials.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Tutorials.gif" BORDER=0 NAME="Tutorials"></A><BR>

<A HREF="/content/hiv-db/REVIEWS/reviews.html" 
	onMouseOver="document.Reviews.src='/content/hiv-db/NAVIFRAME/YELLOW/_Reviews.gif' "
	onMouseOut="document.Reviews.src='/content/hiv-db/NAVIFRAME/YELLOW/Reviews.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Reviews.gif" BORDER=0 NAME="Reviews"></A><BR>

<A HREF="/content/hiv-db/HTML/compendium.html" 
	onMouseOver="document.Compendia.src='/content/hiv-db/NAVIFRAME/YELLOW/_Compendia.gif' "
	onMouseOut="document.Compendia.src='/content/hiv-db/NAVIFRAME/YELLOW/Compendia.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Compendia.gif" BORDER=0 NAME="Compendia"></A><BR>

<A HREF="/content/hiv-db/HTML/links.html" 
	onMouseOver="document.Links.src='/content/hiv-db/NAVIFRAME/YELLOW/_Links.gif' "
	onMouseOut="document.Links.src='/content/hiv-db/NAVIFRAME/YELLOW/Links.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Links.gif" BORDER=0 NAME="Links"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<P>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerSequenceDB.gif" BORDER=0></A><BR>

<!--
<A HREF="/content/hiv-db/MAP/hivmap.html" 
-->
<A HREF="/content/hiv-db/combined_search/search" 
	onMouseOver="document.Hivmap.src='/content/hiv-db/NAVIFRAME/YELLOW/_Search&Align.gif'"
	onMouseOut="document.Hivmap.src='/content/hiv-db/NAVIFRAME/YELLOW/Search&Align.gif'">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Search&Align.gif" BORDER=0 NAME="Hivmap"></A><BR>

<!--
<A HREF="/cgi-bin/hivDB3/public/wdb/ssampublic" 
-->
<A HREF="/content/hiv-db/combined_search/search" 
	onMouseOver="document.Searchdb.src='/content/hiv-db/NAVIFRAME/YELLOW/_SearchDB.gif' "
	onMouseOut="document.Searchdb.src='/content/hiv-db/NAVIFRAME/YELLOW/SearchDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SearchDB.gif" BORDER=0 NAME="Searchdb"></A><BR>

<A HREF="/content/hiv-db/HTML/tools.html" 
	onMouseOver="document.Tools.src='/content/hiv-db/NAVIFRAME/YELLOW/_Tools.gif'"
	onMouseOut="document.Tools.src='/content/hiv-db/NAVIFRAME/YELLOW/Tools.gif'">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Tools.gif" BORDER=0 NAME="Tools"></A><BR>

<A HREF="/content/hiv-db/BASIC_BLAST/basic_blast.html" 
	onMouseOver="document.Hivblast.src='/content/hiv-db/NAVIFRAME/YELLOW/_HIV-BLAST.gif' "
	onMouseOut="document.Hivblast.src='/content/hiv-db/NAVIFRAME/YELLOW/HIV-BLAST.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/HIV-BLAST.gif" BORDER=0 NAME="Hivblast"></A><BR>

<A HREF="http://linker.lanl.gov/RIP/RIPsubmit.html" 
	onMouseOver="document.Rip.src='/content/hiv-db/NAVIFRAME/YELLOW/_Recombination.gif' "
	onMouseOut="document.Rip.src='/content/hiv-db/NAVIFRAME/YELLOW/Recombination.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Recombination.gif" BORDER=0 NAME="Rip"></A><BR>

<A HREF="/content/hiv-db/SNAP/WEBSNAP/SNAP.html" 
	onMouseOver="document.Snap.src='/content/hiv-db/NAVIFRAME/YELLOW/_Syn-Nonsyn.gif' "
	onMouseOut="document.Snap.src='/content/hiv-db/NAVIFRAME/YELLOW/Syn-Nonsyn.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Syn-Nonsyn.gif" BORDER=0 NAME="Snap"></A><BR>

<A HREF="/content/hiv-db/HYPERMUT/hypermut.html" 
	onMouseOver="document.Hypermut.src='/content/hiv-db/NAVIFRAME/YELLOW/_Hypermut.gif' "
	onMouseOut="document.Hypermut.src='/content/hiv-db/NAVIFRAME/YELLOW/Hypermut.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Hypermut.gif" BORDER=0 NAME="Hypermut"></A><BR>

<A HREF="/content/hiv-db/PCOORD/PCOORD.html" 
	onMouseOver="document.Pcoord.src='/content/hiv-db/NAVIFRAME/YELLOW/_PCOORD.gif' "
	onMouseOut="document.Pcoord.src='/content/hiv-db/NAVIFRAME/YELLOW/PCOORD.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/PCOORD.gif" BORDER=0 NAME="Pcoord"></A><BR>
    
<A HREF="/content/hiv-db/SUDI/sudi.html" 
	onMouseOver="document.SUDI.src='/content/hiv-db/NAVIFRAME/YELLOW/_SUDI.gif' "
	onMouseOut="document.SUDI.src='/content/hiv-db/NAVIFRAME/YELLOW/SUDI.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SUDI.gif" BORDER=0 NAME="SUDI"></A><BR>

<A HREF="/content/hiv-db/CONTAM/TreeMaker/TreeMaker.html" 
	onMouseOver="document.Treemaker.src='/content/hiv-db/NAVIFRAME/YELLOW/_TreeMaker.gif' "
	onMouseOut="document.Treemaker.src='/content/hiv-db/NAVIFRAME/YELLOW/TreeMaker.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/TreeMaker.gif" BORDER=0 NAME="Treemaker"></A><BR>

<A HREF="/content/hiv-db/geography/map_right.html" 
	onMouseOver="document.Geography.src='/content/hiv-db/NAVIFRAME/YELLOW/_Geography.gif' "
	onMouseOut="document.Geography.src='/content/hiv-db/NAVIFRAME/YELLOW/Geography.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Geography.gif" BORDER=0 NAME="Geography"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<!--
<br>
<small>
<small>
&nbsp;<a href="/content/hiv-db/combined_search/search">Combined Search</a>
</small>
</small>
</CENTER>
-->
<BR>
<BR>

<center>
<small>
<small>
<A HREF="http://www.lanl.gov/misc/disclaimer.html" >Disclaimer/Privacy</A>
</small>
</small>
<FONT FACE="Arial, Helvetica, sans-serif" SIZE="-2">
</FONT>
</center>

<!--
</BODY>
</HTML>
-->


        </td>
	<td>
	  <table border="0" cellspacing="0" cellpadding="3">
	    <tr><td>
            </td></tr>
	    <tr><td><html>
<head>
<title>Mutations in Retroviral Genes Associated with Drug Resistance</title>
<BODY BGCOLOR = "#FFFFFF"> 
<center><img src="../../IMAGES/DNAhelix.gif"><P>
<font size="+2">Mutations in Retroviral Genes Associated with Drug Resistance</font></center><P>
<hr>
<strong>Jennifer Hammond,</strong><sup>1</sup> <strong>Brendan A. Larder,</strong><sup>2</sup> <strong>Raymond F. Schinazi</strong>
<sup>3</sup> <strong>and John W. Mellors</strong><sup>1</sup>
<p>
<strong><sup>1</sup></strong> University of Pittsburgh, 603 Parran Hall, Pittsburgh, PA  15261. 
<br>
<strong><sup>2</sup></strong> Virco, UK, 162A Cambridge Science Park, Milton Road, Cambridge CB4 4GH.
<br>
<strong><sup>3</sup></strong> Emory University/VAMC, 1670 Clairmont Road, Decatur, GA  30033.
<hr><p>
<strong>Introduction</strong>
<p>
Drug resistance is the inevitable consequence of incomplete suppression of HIV
replication.  The rapid replication rate of HIV and its inherent genetic
variation have led to the identification of many HIV variants that exhibit
altered drug susceptibility. The growing number of drug resistance mutations
listed in this revised table stands as a testimony to the genetic flexibility of
HIV.  This updated table lists 143 mutations occurring in the HIV Gag (3),
Protease (44), Reverse Transcriptase (69), or Envelope (27) genes.  Although
the tables are quite comprehensive, the reader should be reminded that the
mutations described are predominantly found in clade B virus and not in other
HIV genotypes.  The revised table includes for the first time drug resistance
mutations that have been identified for SIV and FIV.
<p>
In the table the phrase "Enzyme resist." refers to inhibition assays done just with a mutated enzyme.
Instead of introducing the mutations into a virus and testing
the susceptibility of the mutant virus to a drug, researchers 
introduce the mutation(s) into the enzyme and
determine their effect by running enzyme activity assays. These sort of
assays don't take into account changes in other viral proteins (like gag)
that would also help confer resistance, which is the reason for
distinguishing enzyme resistance from whole virus resistance.
<p>
<strong>Acknowledgments</strong>
<p>
The authors would like to gratefully acknowledge their colleagues for
assistance in assembling this table. This work was supported in part by the
National Institutes of Health, the Department of Veterans Affairs, and the
Georgia VA Research Center for AIDS and HIV Infections.  
<p>
<strong>Mutations in HIV RT that confer drug resistance, ordered by position.</strong>
<p>
<pre>
Amino Acid    Codon            Class of Drug                    Compound      In         In       -Fold      Cross-resistace         comments                             Refs
  Change     channge                                                         vitro      Vivo   -resistance        (-fold)


  M 41  L   ATG to TTG/CTG    Nucleoside RTI                       AZT         ?          Y         4              -                M41L/T215Y: 60-70-fold;              (1, 2, 3)
                                                                                                                                    M41L/D67N/K70R/T215Y: 180-fold.

  A 62  V   GCC to GTC        Multiple Nucleoside Resistance                   N          Y        Nil             -                A62V alone has no effect, but in     (4, 5)
                                                                                                                                    combination with mutations at 75, 
                                                                                                                                    77, 116, 151 causes multi NRTI 
                                                                                                                                    resistance.

  K 65  R   AAA to AGA        Nucleoside RTI                       ddI         Y          Y        4-10       ddC; PMEA; 3TC(5)     Infrequently observed in patients     (6)
                                                                                                                                    receiving ddI or ddC

  K 65  R   AAA to AGA        Nucleoside RTI                       ddC         Y          Y        4-10              -                           -                        (6, 7)

  K 65  R   AAA to AGA        Nucleoside RTI                     1592U89       Y          N         3                -              K65R/L74V: 3.6-fold;  K65R/M184V:     (8)
                                                                                                                                    7-fold; K65R/L74V/M184V: 10.2-fold
 
  K 65  R   AAA to AGA        Nucleoside RTI                       DXG         Y          ?         8          other dioxolane      Reverses AZT resistance in            (9)
                                                                                                                 derivatives        D67N/K70R/T215Y/K219Q background

  K 65  R   AAA to AGA        Nucleoside RTI                       PMEA        Y          N       10-25               -                         -                         (10, 11)

  K 65  R   AAA to AGA        Nucleoside RTI                       PMPA        Y          ?        3.5                -                         -                         (12)

  D 67  N   GAC to AAC        Nucleoside RTI                        AZT        Y          Y         -                 -             D67N/K70R/T215Y/K219Q: 120-fold;      (1, 2, 3)
                                                                                                                                    M41L/D67N/K70R/T215Y: 180-fold.

  T 69  D   ACT to GAT        Nucleoside RTI                        ddC        N          Y         5                 -                         -                         (13)

  K 70  E   AAA to GAA        Nucleoside RTI                       PMEA        Y          Y         9         3TC (7); PFA: 2-fold              -                         (14, 15)
                                                                                                              hypersusceptibility

  K 70  R   AAA to AGA        Nucleoside RTI                       AZT         Y          Y         -                 -             D67N/K70R/T215Y/K219Q:                (1, 2, 3)
                                                                                                                                          120-fold

  L 74  I   TTA to ATA        HIV-1 Specific RTI                 HBY 097       Y          ?         -                 -                         -                         (16)

  L 74  V   TTA to GTA        Nucleoside RTI                      ddI          N          Y        5-10              ddC(4)         Can reverse effect of T215Y           (17)
                                                                                                                                      AZT resistance mutation

  L 74  V   TTA to GTA        Nucleoside RTI                    1592U89        Y          N         4                  -            K65R/L74V: 3.6-fold;                  (8)
                                                                                                                                    K65R/L74V/M184V: 10.2-fold 

  L 74  V   TTA to GTA        Nucleoside RTI                       DXG         Y          ?         4                  -                      -                           (9)

  L 74  V   TTA to GTA        HIV-1 Specific RTI                 HBY 097       Y          ?         -                  -                      -                           (16)

  V 75  I   GTA to TTA        HIV-1 Specific RTI                 HBY 097       Y          ?         -                  -            Compensates for negative effect 
                                                                                                                                    of G190E mutation on RT activity      (16)

  V 75  I   GTA to ATA        Multiple Nucleoside Resistance        -          N          Y        Nil                  -           V75I alone has no effect, but in      (4, 5)
                                                                                                                                    combination with mutations at 62, 
                                                                                                                                    77, 116, 151 causes multi NRTI 
                                                                                                                                    resistance.

  V 75  L   GTA to ATA        HIV-1 Specific RTI                  HBY 097       Y          ?         -                  -                           -                      (16)

  V 75  T   GTA to ACA        Nucleoside RTI                        d4T         Y          Y         7             ddI; ddC; d4C;   Observed with d4T selection in vitro,  (18, 19)
                                                                                                                      (-)-FTC         rarely in patients receiving d4T
                                                                                                                      
  F 77  L   TTC to CTC        Multiple Nucleoside Resistance         -          N          Y        Nil                 -           F77L alone has no effect, but in       (4, 5)
                                                                                                                                    combination with mutations at 62, 
                                                                                                                                    75, 116, 151 causes multi NRTI 
                                                                                                                                         resistance.

  W 88  G   TGG to GGG        Pyrophosphate Analogue RTI      Foscarnet (PFA)   Y          Y         5         Hypersusceptibility  Observed after selection with AZT      (20, 21, 22)
                                                                                                                      to AZT        and PFA; suppresses effects of AZT  
                                                                                                                                             mutations
                                                                                                                             
  W 88  S   TGG to TCG        Pyrophosphate Analogue RTI      Foscarnet (PFA)   N          Y        2-4        Wild-type suscep-    Partially suppresses effects           (20, 21, 22)
                                                                                                                 -tibility to AZT.

  E 89  G   GAA to GGA        Pyrophosphate Analogue RTI      Foscarnet (PFA)   Y          N        14                 -            Isolated by screening RT clones for    (23)
                                                                                                                                             ddGTP resistance

  E 89  K   GAA to GGA        Pyrophosphate Analogue RTI      Foscarnet (PFA)   Y          N        >16                -            Suppresses effects of AZT resistance   (21, 22)
                                                                                                                                                 mutations

  L 92  I   TTA to ATA        Pyrophosphate Analogue RTI      Foscarnet (PFA)   Y          N         8                 -            Partially suppresses effects of AZT   (21, 22)
                                                                                                                                        resistance mutations

  A 98  G   GCA to GGA          HIV-1 Specific RTI               L-697,661      N          Y         8                 -                             -                     (24)

  A 98  G   GCA to GGA          HIV-1 Specific RTI               Nevirapine     N          Y         -                 -                             -                     (25)

  L 100 I   TTA to ATA          HIV-1 Specific RTI             TIBO R82150      Y          ?       >100                -            suppresses effects of AZT resistance   (26, 27, 28)
                                                                                                                                    mutations

  L 100 I   TTA to ATA          HIV-1 Specific RTI             TIBO R82913      Y          ?         -                 -            Found in combination with E138K        (29)

  L 100 I   TTA to ATA          HIV-1 Specific RTI              L-697,661       Y          N         2                 -                             -                     (24)

  L 100 I   TTA to ATA          HIV-1 Specific RTI             Nevirapine       N          Y         -                 -                             -                     (30)

  L 100 I   TTA to ATA          HIV-1 Specific RTI         DMP 266 (L-743,726)  Y          ?       8-11                -            Combinations of mutations needed for   (31, 32)
                                                                                                                                    high-level resistance; L100I/V108I: 
                                                                                                                                    1,000-fold; L100I/V179D/Y181C: 
                                                                                                                                    1,000-fold

  L 100 I   TTA to ATA          HIV-1 Specific RTI            BHAP U-88204E     Y          ?        -                  -                            -                      (33, 34)

  L 100 I   TTA to ATA          HIV-1 Specific RTI           UC-68 (638532)     Y          ?        70                 -                            -                      (35)

  L 100 I   TTA to ATA          HIV-1 Specific RTI           UC-70 (638534)     Y          ?        758                -                            -                      (36)

  L 100 I   TTA to ATA          HIV-1 Specific RTI              UC-781          Y          ?        20                 -            Activity of UC-781 versus L100I,       (37, 38)
                                                                                                                                    K103N, V106A, E138K, Y181C and Y188L 
                                                                                                                                    reduced by 2-, 7-, 1.5-, 1.5-, 5- and 
                                                                                                                                    150-fold, respectively, compared to 
                                                                                                                                    wild type

  L 100 I   TTA to ATA          HIV-1 Specific RTI            UC-84 (615985)    Y          ?     >40, > 33             -                            -                      (36, 39)

  K 101 E   AAA to GAA          HIV-1 Specific RTI       8-Chloro-TIBO R091767  ?          Y        -                  -                            -                      (40)

  K 101 E   AAA to GAA          HIV-1 Specific RTI   BHAP U-87201E (atevirdine) N          Y        -                  -           K101E, Y188H, E233Y and K238T observed 
                                                                                                                                   with U-87201E/AZT combination therapy   (41)

  K 101 E   AAA to GAA          HIV-1 Specific RTI      DMP 266 (L-743,726)     Y          ?      1,000                -                            -                      (32)

  K 101 E   AAA to GAA          HIV-1 Specific RTI            L-697,661         N          Y        8                  -                            -                      (24)

  K 101 E   AAA to GAA          HIV-1 Specific RTI         UC-10 (645129)       Y          ?       12                  -                  K101E/Y181C: 200-fold            (36, 42, 43)

  K 101 E   AAA to GAA          HIV-1 Specific RTI         UC-38 (629243)       Y          N        -                  -                  K101E/G190E: >100-fold           (36)

  K 101 E   AAA to GAA          HIV-1 Specific RTI         UC-57 (647014)       Y          ?        -                  -                  K101E/Y181C: 58-fold             (36)

  K 101 E   AAA to GAA          HIV-1 Specific RTI             UC781            Y          ?        7     UC040(18);Nevirapine(15)      V108I/ Y181C: 55-fold; 
                                                                                                                                      K101E/ V108I/ Y181C: 500-fold.       (37, 43)

  K 101 I   AAA to ATA          HIV-1 Specific RTI             UC-16            Y          N       10                  -                 K101I/G141E: 10-fold              (36)

  K 101 Q   AAA to CAA          HIV-1 Specific RTI          Trovirdine          Y          ?        -                  -              Found in combination with V108I      (44, 45)

  K 103 N   AAA to AAC          HIV-1 Specific RTI     8-Chloro-TIBO R091767    ?          Y        -                  -                          -                        (40)

  K 103 N   AAA to AAC          HIV-1 Specific RTI  BHAP U-87201E (atevirdine)  N          Y        -                  -                K103N and Y181C observed with      (41)
                                                                                                                                               monotherapy

  K 103 N   AAA to AAC          HIV-1 Specific RTI  BHAP U-90152 (delavirdine)  ?          Y        -                  -            K103N/Y181C seen separately and in     (46)
                                                                                                                                         combination in patients

  K 103 N   AAA to AAC          HIV-1 Specific RTI      DMP 266 (L-743,726)     Y          Y        67                 -              Predominant mutation in vivo         (31)

  K 103 N   AAA to AAC          HIV-1 Specific RTI           L-697,593          Y          ?        20                 -               K103N/Y181C: > 1,000-fold           (47)

  K 103 N   AAA to AAC          HIV-1 Specific RTI           L-697,661          Y          Y         8                 -            K103N and Y181C most common with       (24, 48)
                                                                                                                                              monotherapy

  K 103 N   AAA to AAC          HIV-1 Specific RTI    Loviride (R89439, Ï-APA)  Y          Y         -                 -                        -                          (49)

  K 103 N   AAA to AAC          HIV-1 Specific RTI          MKC442 (I-EBU)      Y          ?         -                 -             predominant mutation in vivo          (50)

  K 103 N   AAA to AAC          HIV-1 Specific RTI          Nevirapine          N          Y         -                 -                        -                          (30)

  K 103 N   AAA to AAC          HIV-1 Specific RTI          TIBO R82913         Y          ?       >100                -                K103N/Y181C: > 1,000-fold          (33)

  K 103 N   AAA to AAC          HIV-1 Specific RTI         UC-10 (645129)       Y          N         5                 -                        -                          (35)

  K 103 N   AAA to AAC          HIV-1 Specific RTI         UC-81 (615727)       Y          ?         40                -                        -     

  K 103 Q   AAA to CAA          HIV-1 Specific RTI           L-697,661          N          Y         8                 -                        -                          (48)

  K 103 R   AAA to AGA          HIV-1 Specific RTI          Trovirdine          Y          ?         -     Nevirapine; 9-chloro-TIBO    K103R/V179D: 500-fold; Found       (44, 45)
                                                                                                                                        in combination with V179D or 
                                                                                                                                               Y181C

  K 103 R   AAA to AGA          HIV-1 Specific RTI         MKC442(1-EBU)        Y          Y         -                 -                        -                          (51)

  K 103 T   AAA to ACA          HIV-1 Specific RTI  BHAP U-90152 (delavirdine)  ?          Y         -                 -                        -                          (46)

  K 103 T   AAA to ACA          HIV-1 Specific RTI           UC-42              Y          N        100                -                        -                          (36)

  V 106 A   GTA to GCA          HIV-1 Specific RTI         BHAP U-88204E        Y          ?         -                 -                        -                          (34)

  V 106 A   GTA to GCA          HIV-1 Specific RTI           E-EBU-dM           Y          ?         -                 -                        -                          (52)

  V 106 A   GTA to GCA          HIV-1 Specific RTI          Nevirapine          Y          Y       ~100                -                No effect on AZT resistance        (25, 29, 30, 33)

  V 106 A   GTA to GCA          HIV-1 Specific RTI         TIBO R82913          Y          ?       ~100                -                        -                          (29)

  V 106 A   GTA to GCA          HIV-1 Specific RTI       UC-69 (646989)         Y          ?         -                 -                  V106A/V181C: 166-fold            (36)

  V 106 A   GTA to GCA          HIV-1 Specific RTI            UC-82             Y          ?        13                 -                Activity of UC-82 versus L100I,    (37, 38)
                                                                                                                                        K103N, V106A, E138K, Y181C and 
                                                                                                                                        Y188L reduced by 2-, 6-, 1.5-, 
                                                                                                                                        2-, 4- and 200-fold, respectively, 
                                                                                                                                          compared to wild type

  V 106 A   GTA to GCA          HIV-1 Specific RTI     S-2720 (Quinoxaline)     Y          ?         -                 -                P225H follows V106A.  Also seen    (53)
                                                                                                                                        with L101I and Y181C.  Double and 
                                                                                                                                        triple mutants highly resistant to 
                                                                                                                                        other NNRTI's, including MKC442

  V 106 I   GTA to ATA          HIV-1 Specific RTI          HBY 097            -           -         -                 -                   Appears under lowered drug      (54)
                                                                                                                                            concentration selection

  V 108 I   GTA to ATA          HIV-1 Specific RTI     DMP 266 (L-743,726)     Y           ?         -                 -                  L100I/V108I: 1,000-fold          (31)

  V 108 I   GTA to GCA          HIV-1 Specific RTI         L-697,661           Y           Y         4                 -                        -                          (24)

  V 108 I   GTA to ATA          HIV-1 Specific RTI   Loviride (R89439, Ï-APA)  Y           ?         -                 -                        -                          (49)

  V 108 I   GTA to GCA          HIV-1 Specific RTI        MKC442 (I-EBU)       Y           ?         -                 -                        -                          (50)

  V 108 I   GTA to ATA          HIV-1 Specific RTI         Nevirapine          N           Y         -                 -                        -                          (30)

  V 108 I   GTT to GAT          HIV-1 Specific RTI        TIBO R82913          N           Y       >100          R82150 (> 100)                 -                          (55)

  V 108 I   GTA to ATA          HIV-1 Specific RTI         Trovirdine          Y           ?         -                 -               Found in combination with K101Q     (44, 45)

  V 108 I   GTA tO ATA          HIV-1 Specific RTI           UC781             Y           ?         -                 -               V108I/Y181C:  55 fold.  K101E/V108I (43)
                                                                                                                                           /Y181C: 500 fold.

  Y 115 F   TAT to TTT           Nucleoside RTI             1592U89            Y           N         2                 -               K65R/L74V and/or Y115F with M184V:  (8)
                                                                                                                                      10 fold; L74V/Y115F/M184V: 11-fold

  F 116 Y   TTT to TAT     Multiple Nucleoside Resistance      -               N           Y        Nil                -               F116Y alone has no effect, but in   (4, 5)
                                                                                                                                       combination with mutations at 62, 
                                                                                                                                       75, 77, 151 causes multi NRTI 
                                                                                                                                                  resistance.

  P 119 S   CCC to TCC         Nucleoside RTI                F-ddA             Y           ?         4                 -               Found with V179D and/or L214F,      (56)
                                                                                                                                       which are possibly compensatory

  E 138 K   GAG to AAG         HIV-1 Specific RTI             TSAO             Y           ?       >100                -               E138A (GAG to GCG) in TSAO-naive    (57, 58, 59)
                                                                                                                                       patients confers TSAO viral 
                                                                                                                                              resistance
  E 138 K   GAG to AAG         HIV-1 Specific RTI          MKC442 (I-EBU)      Y           N         -                 -              Obtained in the concomitant presence (60)
                                                                                                                                          of low 3TC concentrations

  E 138 K   GAG to AAG         HIV-1 Specific RTI           TIBO R82913        Y           ?         -                 -              Found in combination with L100I      (27)

  E 138 K   GAG to AAG         HIV-1 Specific RTI            UC-82             Y           ?         5                 -              Activity of UC-82 versus L100I,      (37, 38)
                                                                                                                                      K103N, V106A, E138K, Y181C and Y188L 
                                                                                                                                      reduced by 2-, 6-, 1.5-, 2-, 4- and 
                                                                                                                                      200-fold, respectively, compared to 
                                                                                                                                           wild type

  E 138 K   GAG to AAG         HIV-1 Specific RTI          UC-84 (615985)      Y           ?        >100             TSAOs                            -                    (35, 61)

  T 139 I   ACA to ATA         HIV-1 Specific RTI           Calanolide A       Y           ?        >70          Not other NNRTIs                     -                    (39)

  G 141 E   GGG to GAG         HIV-1 Specific RTI            UC-16             Y           N         -                 -                 K101I/G141E: 10-fold              (35)

  Q 151 M   CAG to ATG   Multiple Nucleoside Resistance        -               N           Y  AZT: 10; ddI/  ddC: 5    -                Pivotal multi nucleoside RTI       (4, 5, 62)
                                                                                                                                      resistance mutation (first to occur), 
                                                                                                                                          found in association with 
                                                                                                                                      combinations of four other mutations:  
                                                                                                                                       A62V/ V75I/ F77L/ F116Y/Q151M:  AZT 
                                                                                                                                      190-fold; ddI 50-fold; ddC 20-fold; 
                                                                                                                                            d4T > 10-fold

  S 156 A   TCA to GCA      Pyrophosphate Analogue RTI      Foscarnet (PFA)    Y           N         4.5               -                            -                      (21)

  Q 161 L   CAA to CTA      Pyrophosphate Analogue RTI      Foscarnet (PFA)    Y           Y          5                -               Q161L/H208Y: 9-fold; Q161L/H208Y    (20)
                                                                                                                                     suppresses effects of AZT mutations

  V 179 D   GTT to GAT         HIV-1 Specific RTI        DMP 266 (L-743,726)   Y           ?          -                -                L100I/V179D/Y181C: 1,000-fold      (31)

  V 179 D   GTT to GAT         HIV-1 Specific RTI            L-697,661         N           Y          4                -                            -                      (24)

  V 179 D   GTT to GAT         HIV-1 Specific RTI           TIBO R82913        N           Y         20           R82150 (20)                       -                      (63)

  V 179 D   GTT to GAT         HIV-1 Specific RTI          Trovirdine          Y           ?          -                -             Found in combination with K103R or    (44, 45)
                                                                                                                                     Y181C; V179D/Y181C: > 1,000-fold

  V 179 D   GTT to GAT         HIV-1 Specific RTI          UC-10 (645129)      Y           ?         16                -                            -                      (35)

  V 179 E   GTT to GAG         HIV-1 Specific RTI         L-697,661            N           Y          8                -                            -                      (23)

  Y 181 C   TAT to TGT         HIV-1 Specific RTI    Ï-APA R18893 (loviride-   Y           ?          -                -                            -                      (64)
                                                          -analogue)

  Y 181 C   TAT to TGT         HIV-1 Specific RTI  BHAP U-87201E (atevirdine)  N           Y          -                -       K103N and Y181C observed with monotherapy   (46)

  Y 181 C   TAT to TGT         HIV-1 Specific RTI        BHAP U-88204E         Y           ?          -                -                        -                          (34)

  Y 181 C   TAT to TGT         HIV-1 Specific RTI  BHAP U-90152 (delavirdine)  ?           Y          -                -          K103N/Y181C seen separately and in       (46)
                                                                                                                                      combination in vivo

  Y 181 C   TAT to TGT         HIV-1 Specific RTI       BM+51.0836             Y           ?          -                -                            -                      (65)

  Y 181 C   TAT to TGT         HIV-1 Specific RTI     DMP 266 (L-743,726)      Y           ?          4                -        L100I/V179D/Y181C: 1,000-fold; uncommon    (31, 32)
                                                                                                                                            in vivo

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         E-EBU                Y           ?          -                -                           -                       (52)

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         E-EPSeU              Y           ?          >50              -      Y188C confers greater resistance than Y181C  (66)

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         E-EPU                Y           ?          >95              -      Y188C confers greater resistance than Y181C  (66) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         MKC442 (1-EBU)       ?           Y          -                -                           -                       (51) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         L-697,593            Y           ?          >100             -      K103N/Y181C: > 1,000-fold                    (47) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         L-697,661            Y           Y          >30              -      K103N and Y181C most common 
                                                                                                                              with monotherapy                             (24, 48) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         Loviride 
                                                          (R89439, Ï-APA)      ?           Y          -                -                           -                       (67) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         Nevirapine           Y           Y          >100       Other NNRTIs Can suppress 
                                                                                                                              effects of AZT mutations                     (25, 68, 69) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         NSC 648400 
                                                          (E-BPTU)             Y           ?          160        Other NNRTIs                      -                       (70) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         TIBO R82913          Y           ?          >100             -      K103N/Y181C:> 1,000-fold                     (29) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         Trovirdine           Y           ?          -          Nevirapine; 
 n                                                                                                               9-chloro-
                                                                                                                 TIBO         V179D/Y181C:> 1,000-fold; 
                                                                                                                              Found in combination with K103R or V179D     (44, 45) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         UC-10 
                                                          (645129)             Y           ?          6                -      K101E/Y181C: 200-fold                        (36, 42) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         UC-32 
                                                          (645542)             Y           ?          3                -                           -                       (36) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         UC-38 
                                                          (629243)             Y           ?         8-149       Other NNRTIs                      -                       (36, 71) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         UC-040               Y           ?         16                -                           -                       (42) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         UC-57 
                                                          (647014)             Y           ?         -                 -      K101E/Y181C: 58-fold                         (36) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         UC-68 
                                                          (638532)             Y           ?         5                 -                            -                      (36) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         UC-69 
                                                          (646989)             Y           ?         -                 -      V106A/V181C: 166-fold                        (36) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         UC-80 
                                                          (639475)             Y           ?         1                 -                            -                      (36) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         UC-81 
                                                          (615727)             Y	   ?         53                -                            -                      (35, 72) 

  Y 181 C   TAT to TGT	       HIV-1 Specific RTI	  UC-82		       Y	   ?         5                 -                            -                      (42) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         UC-84 
                                                          (615985)             Y	   ?         >11               -                            -                      (36) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         UC781                Y           ?         13                -     V108/ Y181C:  55 fold; K101E/ 
                                                                                                                             V108I/ Y181C: 500 fold.                       (42) 

  Y 181 C   TAT to TGT         HIV-1 Specific RTI         1737 
                                                     (Tetrahydronaphthalene 
                                                     derivative)               Y           ?         20                -     Y181C also confers resistance 
                                                                                                                             to numerous other 
                                                                                                                             tetrahydronaphthalene derivative              (73)

  Y 181 I    TGT to ATT        HIV-1 Specific RTI         BHAP U-88204E        Y           Y          -                -     Appeared after treatment of Y181C-
                                                                                                                             mutated virus with BHAP; high-level 
                                                                                                                             resistance to BHAP, nevirapine and 
                                                                                                                             TIBO; observed in one nevirapine-
                                                                                                                             treated patient                               (74) 

  Y 181 I    TAT to ATT        HIV-1 Specific RTI     MKC442 (I-EBU)           Y           N       1,000              -                    -                               (60) 

  Y 181 I    TGT to ATT        HIV-1 Specific RTI     Nevirapine               N           Y       High-level         -      Observed in one patient                       (75) 

  M 184 I    ATG to ATA        Nucleoside RTI         3TC (lamivudine)         Y           Y        -                 -      M184V and M184I can suppress 
                                                                                                                             effects of AZT resistance mutations           (76, 77, 78)   

  M 184 T        -             Nucleoside RTI         3TC (lamivudine)         Y           ?        -                 -      Reduced replication capacity and RT 
                                                                                                                             activity                                      (79, 80) 

  M 184 V    ATG to GTG        Nucleoside RTI         3TC (lamivudine)         Y           Y      >100          ddI; ddC; 
                                                                                                                (-)-FTC      M184V and M184I can suppress effects 
                                                                                                                             of AZT resistance mutations; GTA seen 
                                                                                                                             in cell culture                               (76, 77, 78) 

  M 184 V    ATG to GTG        Nucleoside RTI         (-)-FTC                  Y           ?      >100               -       M184V can suppress effects of AZT 
                                                                                                                             mutations                                     (76, 77) 

  M 184 V    ATG to GTG        Nucleoside RTI         1592U89                  Y           N      3                  -       K65R/L74V and/or Y115F with M184V: 
                                                                                                                             10-fold; K65R/M184V: 8-fold; L74V/
                                                                                                                             M184V: 9-fold resistance; L74V/Y115F
                                                                                                                             /M184V: 11-fold                               (8) 

  M 184 V    ATG to GTG        Nucleoside RTI           ddC                    Y           Y      2-5                -                  -                                 (81) 

  M 184 V    ATG to GTG        Nucleoside RTI           ddI                    Y           Y      2-5                -      Rarely observed in patients receiving ddI      (81) 

  M 184 V    ATG to GTG        Nucleoside RTI         L-FddC                   Y           ?      >100               -                 -                                   (82) 

  Y 188 C    TAT to TGT        HIV-1 Specific RTI     E-EPSeU                  Y           ?      >250               -      Y188C is the predominant mutation for 
                                                                                                                            E-EPSeU; Y188C confers greater resistance 
                                                                                                                            than Y181C                                     (66) 

  Y 188 C    TAT to TGT        HIV-1 Specific RTI     E-EPU                    Y           ?      >250               -      Y188C confers greater resistance 
                                                                                                                            than Y181C                                     (66) 

  Y 188 C    TAT to TGT        HIV-1 Specific RTI     HEPT                     Y           ?       -                 -                  -                                  (52) 

  Y 188 C    TAT to TGT        HIV-1 Specific RTI     Nevirapine               N           Y       -                 -                  -                                  (30) 

  Y 188 H    TAT to CAT        HIV-1 Specific RTI     BHAP U-87201E 
                                                      (atevirdine)             N           Y       -                 -      K101E, Y188H, E233Y and K238T 
                                                                                                                            observed with U-87201E/AZT 
                                                                                                                            combination therapy                            (41) 

  Y 188 H    TAT to CAT        HIV-1 Specific RTI     TIBO R82913              Y           ?       -                 -                  -                                  (27) 

  Y 188 H/L  TAT to CAT/CTT    HIV-1 Specific RTI     Loviride (R89439,  
                                                      Ï-APA)                   ?           Y       -                 -                  -                                  (67) 
  Y 188 L    TAT to TTA        HIV-1 Specific RTI     DMP 266 (L-743,726)      Y           ?     1,000               -                  -                                  (31) 

  Y 188 L    TAT to TTA        HIV-1 Specific RTI     TIBO R82913              N           Y       -                 -                  -                                  (63) 

  V 189 I    GTA to ATA        HIV-1 Specific RTI     HBY 097                  Y           ?      2         Other NNRTIs 
                                                                                                                (2-6)                   -                                  (16) 
  
  G 190 A    GGA to GCA        HIV-1 Specific RTI     Loviride (R89439, 
                                                      Ï-APA)                   ?           Y      -                 -                   -                                  (83) 
  G 190 A    GGA to GCA        HIV-1 Specific RTI     Nevirapine               N           Y      -                 -                   -                                  (25) 

  G 190 E    GGA to GAA        HIV-1 Specific RTI     AAP-BHAP (U-104489)      Y           ?     >100               -       T139I/ G190E/ T200A/ L214F:  
                                                                                                                            >100.  Additional mutations possibly 
                                                                                                                            restore the replication capacity of 
                                                                                                                            the G190E mutant                               (84) 

  G 190 E    GGA to GAA        HIV-1 Specific RTI     HBY 097                  Y           ?      -        Other NNRTIs     Reduces enzymatic activity of RT 
                                                                                                                            and viral replication competency               (85) 

  G 190 E    GGA to GAA        HIV-1 Specific RTI     S-2720                   Y           ?      -                -                   -                                   (86) 

  G 190 E    GGA to GAA        HIV-1 Specific RTI     UC-38 (629243)           Y           N      -                         K101E/G190E: >100-fold; cross resistance 
                                                                                                                            to: TSAO-m3T, Nev, TIBO R82913, BHAP 
                                                                                                                            U88204; susceptible to L697,661                (35, 43) 

  G 190 E    GGA to GAA        HIV-1 Specific RTI     AAP-BHAP (U-95133)       Y           ?    >100               -        T139I/ G190Q/ T200A/ L214F:  >100-fold.  
                                                                                                                            Additional mutations possibly restore 
                                                                                                                            the replication compentency of the G190E 
                                                                                                                            mutant.                                        (84) 

  G 190 Q    GGA to CAA        HIV-1 Specific RTI     HBY 097                  Y           ?     -        Other NNRTIs      Appears exclusively in connection with V179D   (16) 

  G 190 T    GGA to ?          HIV-1 Specific RTI     HBY 097                  -           -     -                 -        Appears under lowered drug concentration 
                                                                                                                            selection                                      (54) 

  H 208 Y    CAT to TAT        Pyrophosphate 
                               Analogue RTI           Foscarnet (PFA)          Y           Y     -                 2        Q161L/H208Y: 9-fold; increased susceptibility 
                                                                                                                            to AZT (100-fold), nevirapine (20-fold) 
                                                                                                                            and TIBO R82150 (30-fold); Q161L/H208Y 
                                                                                                                            suppresses effects of AZT mutations            (20) 

  H 208 Y    CAT to TAT        Multiple Nucleoside 
                               Resistance             AZT + 3TC                ?           Y     -                 -        Polymorphism facilitating AZT+3TC dual 
                                                                                                                            resistance                                     (87) 

  L 210 W    TTG to TGG        Nucleoside RTI         AZT                      Y           Y     -                 -        210W/215Y:  42-fold 41L/210W/215Y:  
                                                                                                                            49-fold  41L/67N/70R/210W/215Y:  
                                                                                                                            366-fold Mutation arises after prolonged 
                                                                                                                            AZT therapy.                                   (88, 89, 90) 

  R 211 K    AGG to AAG        Multiple 
                               Nucleoside Resistance  AZT + 3TC                ?           Y     -                 -        Polymorphism facilitating AZT+3TC dual 
                                                                                                                            resistance in association with M184V and 
                                                                                                                            other AZT resistance mutations.                (87) 

  L 214 F    CTT to TTT        Multiple 
                               Nucleoside Resistance  AZT + 3TC                ?           Y     -                 -        Polymorphism facilitating AZT+3TC dual 
                                                                                                                            resistance in association with  M184V and 
                                                                                                                            other AZT resistance mutations.                (87, 91) 

  T 215 F    ACC to TTC        Nucleoside RTI         AZT                      ?           Y     -                 -        K67N/K70R/T215Y/K219Q: 120-fold                (1, 2, 3) 

  T 215 Y    ACC to TAC        Nucleoside RTI         AZT                      Y           Y     -                 -        M41L/T215Y: 60-70-fold; K67N/K70R/
                                                                                                                            T215Y/K219Q: 120-fold.  Effect of T215Y 
                                                                                                                            is reversed by a ddI mutation (L74V), 
                                                                                                                            NNRTI mutations (L100I;Y181C) or 
                                                                                                                            (-)-FTC/3TC mutations (M184I/V)                (1, 2, 3) 

  Y 215 C    TTC to TGC        Nucleoside RTI         ddC                      N           Y     4                -         Arises on background of T215Y 
                                                                                                                            AZT resistance                                 (92) 

  K 219 E    AAA to GAA        Nucleoside RTI         AZT                      Y           N     -                -                       -                                (1, 2, 3)  

  K 219 Q    AAA to CAA        Nucleoside RTI         AZT                      ?           Y     -                -         K67N/K70R/T215Y/K219Q: 120-fold                (1, 2, 3) 

  P 225 H    CCT to CAT        HIV-1 Specific RTI     S-2720 (Quinoxaline)     Y           ?     -                -         P225H follows V106A.  Also seen with 
                                                                                                                            L101I and Y181C.  Double and triple 
                                                                                                                            mutants highly resistant to other 
                                                                                                                            NNRTI's, including MKC442.                     (53) 
  E 233 V    GAA to GTA        HIV-1 Specific RTI     BHAP U-87201E 
                                                      (atevirdine)             N           Y     -                -         K101E, Y188H, E233Y and K238T observed 
                                                                                                                            with U-87201E/AZT combination therapy          (41) 

  P 236 L    CCT to CTT        HIV-1 Specific RTI     BHAP U-87201E 
                                                      (atevirdine)             Y           N     -                -                      -                                 (93) 

  P 236 L    CCT to CTT        HIV-1 Specific RTI     BHAP U-90152 
                                                      (delavirdine)            Y           Y     -                -         Sensitizes RT ~10-fold to nevirapine, 
                                                                                                                            TIBO R82913 and L-697,661                      (93) 

  P 236 L    CCT to CTT        HIV-1 Specific RTI     HEPT                     Y           ?     -                -                      -                                 (70) 

  K 238 T    AAA to ACA        HIV-1 Specific RTI     BHAP U-87201E 
                                                      (atevirdine)             N           Y     -                -         K101E, Y188H, E233Y and K238T observed 
                                                                                                                            with U-87201E/AZT combination therapy          (41) 

  G 333 D    GGC to GAC        Multiple Nucleosides   AZT+3TC                  Y           Y     -                -         Facilitates dual resistance to AZT+3TC 
                                                                                                                            in association with M184V and standard 
                                                                                                                            AZT resistance mutations.                      (87) 

  G 333 E    GGC to GAG        Multiple Nucleosides   AZT + 3TC                Y           Y     -                -         Facilitates dual resistance to AZT+3TC 
                                                                                                                            in association with M184V and standard 
                                                                                                                            AZT resistance mutations.                      (87) 

</pre>
<strong>Mutations in Protease and Drug Resistance</strong>
<pre>
  K 65 R    AAA to AGA        Nucleoside RTI              ddC                  Y          Y        4-10              -                           -                        (6, 7)

  R 8  K    CGA to AAA        Protease Inhibitor        A-77003                Y          ?         10               -               R8K/  M46I/  G48V: 20-fold           (94, 95)
 
  R 8  Q    CGA to CAA        Protease Inhibitor        A-77003                Y          ?         10               -               M46I improves replication 
                                                                                                                                     competency of R8Q mutant             (94, 96) 
  
  L 10 F    CTC to TTC        Protease Inhibitor        DMP 450                Y          ?         -                -               Probably compensatory                (97, 98) 
  
  L 10 F    CTC to GGC        Protease Inhibitor        VB 11,328              Y          ?         -                -               L10F/I84V: 8-fold                    (99) 
  
  L 10 F    CTC to CGC        Protease Inhibitor        VX-478 (141W94)        Y          ?         -                -                     -                              (100) 
  
  L 10 F    CTC to CGC        Protease Inhibitor         XM323                 -          -         -        L10F/  V82A: 2-fold;    L10F/  K45I/  I84V: 50-fold          (101)
    
  L 10 F    CTC to CGC        Protease Inhibitor        SC-55389A              Y          ?         2.8      Not SC-52151            N88S/L10F: 25-fold                   (102, 103, 104) 
 
  L 10 F    CTC to TTC        Protease Inhibitor        BILA 2185 BS           Y          ?         -        BILA 1906 BS (360)      L10F/ L23I/ V32I/ M46I/ I47V/ 
                                                                                                                                     I54M/ A71V/ I84V:  1,500-fold.  
                                                                                                                                     Associated Gag mutations:  p1/p6 
                                                                                                                                     cleavage site (L to F (CTT to 
                                                                                                                                     TTT at P1'); p7/p1 cleavage site 
                                                                                                                                     (Q to R (CAG to CGG) at P3', 
                                                                                                                                     A to V (GCT to CTT) at P2'.      (106) 
 
  L 10 I    CTC to ATC        Protease Inhibitor        MK-639 (L-735
                                                        ,524, indinavir)       ?          Y        -         -                                                        (105) 

  L 10 I       -              Protease Inhibitor        Ro 31-8959
                                                        (saquinavir)           -          Y        -         -                       Found in combination with 
                                                                                                                                     G48V in vivo                     (107) 

  L 10 R    CTC to CGC        Protease Inhibitor        MK-639 (L-735,524, 
                                                        indinavir)             -          N        Y        XM-323 (15)              L10R/  M46I/  L63P/  V82T: 
                                                                                                                                     4-fold; L10R/  M46I/  L63P/  
                                                                                                                                     V82T/  I84V: 8-fold              (105) 

  L 10 V    CTC to GTC        Protease Inhibitor        MK-639 (L-735,524, 
                                                        indinavir)             ?          Y        -        A-80987 (4)                       -                       (105) 

  K 20 M    AAG to ATG        Protease Inhibitor        MK-639 (L-735,524, 
                                                        indinavir)             ?          Y        -        VX-478 (8)                        -                       (105) 

  K 20 R    AAG to AAA        Protease Inhibitor        ABT-538 (ritonavir)    N          Y        -          -                      K20R/M36I/I54V/V82A: 41-fold     (108) 

  K 20 R    AAG to AAA        Protease Inhibitor        MK-639 (L-735,524, 
                                                        indinavir)             ?          Y        -        Ro-31-8959 (8);                  -                        (105) 

  L 23 I    CTA to ATA        Protease Inhibitor        BILA 2185 BS           Y          ?        -        Ro 31-8959 (50);L-735,
                                                                                                            524 (80); BILA 1906 
                                                                                                            BS (360)                 L10F/ L23I/ V32I/ M46I/ I47V/ 
                                                                                                                                     I54M/ A71V/ I84V:  1,500-fold.  
                                                                                                                                     Associated Gag mutations:  p1/p6                
                                                                                                                                     cleavage site (L to F (CTT to 
                                                                                                                                     TTT at P1'); p7/p1 cleavage site 
                                                                                                                                     (Q to R (CAG to CGG) at P3', 
                                                                                                                                     A to V (GCT to CTT) at P2'.      (106, 109) 

  L 24 I    TTA to ATA        Protease Inhibitor        MK-639 (L-735,524, 
                                                        indinavir)             ?          Y        -        SC-52151 (8)             -                                (105)  

  L 24 V    TTA to GTA        Protease Inhibitor        SC-52151               Y          ?      10-20      SC55389A                 L24V/  G48V/  A71V/  
                                                                                                                                     V75I/  P81T: 1000-fold           (102, 103) 

  D 30 N    GAT to AAT        Protease Inhibitor        AG1343 
                                                        (nelfinavir)           Y          Y        -           -                     D30N/A71V: 7-fold; D30N
                                                                                                                                     and N88D are most common 
                                                                                                                                     in vivo after 24 weeks of 
                                                                                                                                     therapy; they do not cause 
                                                                                                                                     cross-resistance to other
                                                                                                                                     protease inhibitors              (110, 111) 
 
  V 32 I    GTA to ATA        Protease Inhibitor        ABT-538 (ritonavir)    Y          ?        40          -                     V32I and V82I are synergistic 
                                                                                                                                     mutations yielding 20-fold 
                                                                                                                                     enzyme resistance                (108) 
 
  V 32 I    GTA to ATA        Protease Inhibitor        A-77003                Y          ?        7 
                                                                                              (enzyme resist.) -                     V32I appears first; progression 
                                                                                                                                     to V32I/  M46V and V32I/  /  
                                                                                                                                     M46V/  A71V/  V82A occurs even 
                                                                                                                                     in the absence of drug           (96) 

  V 32 I    GTA to ATA        Protease Inhibitor        BILA 1906 BS           Y          ?       -            -                     V32I/  A71V: 3-fold; V32I/  
                                                                                                                                     M46I,L/ A71V/  I84V: 5-fold; 
                                                                                                                                     V32I/ M46I,L/ A71V/ I84A:  
                                                                                                                                     520-fold.  32I/ 46L/ 71V/ 
                                                                                                                                     84A are functionally impaired.  
                                                                                                                                     Associated Gag mutations:  
                                                                                                                                     p1/p6 cleavage 
                                                                                                                                     site (L to F 
                                                                                                                                     (CTT to TTT at P1')              (112, 106) 

  V 32 I    GTA to ATA        Protease Inhibitor        BILA 2011 
                                                        (palinavir)            Y          ?      1200         BILA 1906 (1400)       Other mutations found in 
                                                                                                                                     p1/  p6 cleavage site            (113) 

  V 32 I    GTA to ATA        Protease Inhibitor        KNI-272                Y          ?       2                 -                V32I/  M46I/  I84V: 37-fold;
                                                                                                                                     V32I/  L33F/  K45I/  F53L/  
                                                                                                                                     A71V/  I84V/  L89M: 130-fold     (114) 

  V 32 I    GTA to ATA        Protease Inhibitor        MK-639 (L-735, 
                                                        524, indinavir)        Y          Y       -                 -                V32I/  M46L/  V82A: 3-fold;
                                                                                                                                       V32I/  M46L/  A71V/  V82A:
                                                                                                                                      14-fold                         (105) 

  V 32 I    GTA to ATA        Protease Inhibitor        BILA 2185 BS           Y          ?       -          BILA 1906 (360)         L10F/ L23I/ V32I/ M46I/ I47V/ 
                                                                                                                                     I54M/ A71V/ I84V:  1,500-fold.  
                                                                                                                                     Associated Gag mutations:  
                                                                                                                                     p1/p6 cleavage site (L to F 
                                                                                                                                     (CTT to TTT at P1'); p7/ p1 
                                                                                                                                     cleavage site (Q to R 
                                                                                                                                     (CAG to CGG) at P3', A to V 
                                                                                                                                     (GCT to CTT) at P2'.             (106) 

  L 33 F    TTA to TTC        Protease Inhibitor        ABT-538 (ritonavir)    N          Y       -                -                 M36I/I54V/A71V/V82I: 8-fold; 
                                                                                                                                     K20R/M36I/I54V/V82A: 41-fold. 
                                                                                                                                     In vivo, V82A/F/T/S occurs first,
                                                                                                                                     often followed by changes at 
                                                                                                                                     54,71 and 36                     (108) 

  M 36 I    ATG to ATA        Protease Inhibitor        ABT-538 (ritonavir)    N          Y       -                -                 In vivo, V82 occurs first, 
                                                                                                                                     often followed by changes at 
                                                                                                                                     54, 71 and 36                    (108) 

  M 36 I         -            Protease Inhibitor        AG1343 (nelfinavir)    -          Y       -                -                            -                     (110) 

  K 45 I    AAA to ATA        Protease Inhibitor        XM323                  -          -       -                -                 L10F/  K45I/  I84V: 
                                                                                                                                     50-fold                          (95) 

  M 46 F    ATG to TTC        Protease Inhibitor        A-77003                Y          ?       4 
                                                                                               (enzyme resist.)    -                 Seen with V82A                   (96) 

  M 46 I    ATG to ATA        Protease Inhibitor        A-77003                Y          ?       -                -                 No effect on susceptibility 
                                                                                                                                     but improves replication 
                                                                                                                                     competency of R8Q mutant; 
                                                                                                                                     R8K/  M46I/  G48V: 20-fold       (94, 96) 

  M 46 I    ATG to ATA        Protease Inhibitor        ABT-538 (ritonavir)    Y          Y       -                -                 M46I/  L63P/  A71V/  V82F/  
                                                                                                                                     I84V: 27-fold                    (108) 

  M 46 I    ATG to ATA        Protease Inhibitor        AG1343 (nelfinavir)    Y          Y       -                -                          -                       (110) 

  M 46 I    ATG to ATA        Protease Inhibitor        BILA 1906 BS           Y          ?       -                -                 L 735,524 (60)&V32I/  A71V: 
                                                                                                                                     3-fold; V32I/  M46I,L/ A71V/  
                                                                                                                                     I84V: 5-fold; V32I/ M46I,L/ 
                                                                                                                                     A71V/ I84A:  520-fold.  V32I/
                                                                                                                                     M46L/A71V/I84A is functionally 
                                                                                                                                     impaired.  Associated Gag 
                                                                                                                                     mutations:  p1/p6 cleavage site 
                                                                                                                                     (L to F (CTT to TTT at P1')     (106, 109, 112, 113) 

  M 46 I    ATG to ATA        Protease Inhibitor        BILA 2185 BS           Y          ?      -             BILA 1906 (360)       L10F/ L23I/ V32I/ M46I/ I47V/ 
                                                                                                                                     I54M/ A71V/ I84V:  1,500-fold.  
                                                                                                                                     Associated Gag mutations:  
                                                                                                                                     p1/p6 cleavage site (L to F 
                                                                                                                                     (CTT to TTT at P1'); p7/p1 
                                                                                                                                     cleavage site (Q to R 
                                                                                                                                     (CAG to CGG) at P3', A to V 
                                                                                                                                     (GCT to CTT) at P2'.            (106) 
        
  M 46 I    ATG to ATA        Protease Inhibitor        DMP 450                Y          ?      -                 -                 Probably compensatory           (97, 98)


  M 46 I    ATG to ATA        Protease Inhibitor        MK-639 (L-735,524,
                                                         indinavir)            N          Y      -                 -                 M46I/  L63P/  V82T: 4-fold; 
                                                                                                                                     L10R/  M46I/  L63P/  V82T: 
                                                                                                                                     4-fold; L10R/  M46I/  L63P/  
                                                                                                                                     V82T/  I84V: 8-fold            (105, 115) 

  M 46 I    ATG to ATA        Protease Inhibitor        VB 11,32               Y          ?     -                  -                 I50V/  M46I/  I47V: 
                                                                                                                                     20-fold                        (95, 99) 

  M 46 I    ATG to ATA        Protease Inhibitor        VX-478 (141W94)        Y          ?    Nil                 -                            -                       - 

  M 46 L    ATG to TTC        Protease Inhibitor        A-77003                Y          ?    2-3 
                                                                                            (enzyme resist.)       -                            -                   (96)
     
  M 46 L    ATG to TTG        Protease Inhibitor        BILA 1906 BS           Y          ?     -                  -                Associated p1/  p6 cleavage 
                                                                                                                                    site mutation (L to F 
                                                                                                                                    (CTT to TTT) at P1'             (106, 109, 112, 113) 

  M 46 L    ATG to TTG        Protease Inhibitor        MK-639 (L-735,524,
                                                         indinavir)            Y          Y     -                  -                V32I/  M46L/  A71V/  V82A: 
                                                                                                                                    14-fold; V32I/  M46L/  
                                                                                                                                    V82A: 3-fold&(95)\cr

  M 46 L    ATG to CTG        Protease Inhibitor        XM323                  Y          ?     -                  -                V82A/  M46L: 7-fold; V82A/
                                                                                                                                    M46L/  L97V: 11-fold            (101) 

  M 46 V        -             Protease Inhibitor        A-77003                Y          ?     -                  -                V32I appears first; progression 
                                                                                                                                    to V32I/  M46V and V32I/  /  
                                                                                                                                    M46V/  A71V/  V82A occurs even 
                                                                                                                                    in the absence of drug          (95) 

  I 47 V    ATA to CTA        Protease Inhibitor        VB 11,328              Y          ?     -                  -                I50V/  M46I/  I47V: 20-fold      -

  I 47 V    ATA to CTA        Protease Inhibitor        VX-478 (141W94)        Y          ?    Nil                 -                             -                   - 

  I 47 V    ATA to CTA        Protease Inhibitor        BILA 2185 BS           Y          ?     -             BILA 1906 (360)       L10F/ L23I/ V32I/ M46I/ I47V/ 
                                                                                                                                    I54M/ A71V/ I84V:  1,500-fold.  
                                                                                                                                    Associated Gag mutations:  
                                                                                                                                    p1/p6 cleavage site (L to F 
                                                                                                                                    (CTT to TTT at P1'); p7/p1 
                                                                                                                                    cleavage site (Q to R (CAG 
                                                                                                                                    to CGG) at P3', A to V 
                                                                                                                                    (GCT to CTT) at P2'.            (106) 

  G 48 V    GGG to GTG        Protease Inhibitor        A-77003                Y          ?    -                  -                 R8K/  M46I/  G48V: 20-fold; 
                                                                                                                                    G48V/  I82T: 100-fold           (116) 

  G 48 V    GGG to GTG        Protease Inhibitor        Ro 31-8959 
                                                        (saquinavir)           Y          Y    -                  -                 Found in comb. with L10I in 
                                                                                                                                    vivo; G48V/  I84V/  L90M: 
                                                                                                                                    30-fold; G48V/  L90M: >100-fold 
                                                                                                                                    enzyme resistance; G48V/  L90M/  
                                                                                                                                    I54V: > 50-fold 
                                                                                                                                    (subtype B or O)                (117, 118) 

  G 48 V    GGG to GTG        Protease Inhibitor        SC-52151               Y          ?    -                  -                 Ro 31-8959&G48V/  V82A, G48V/  
                                                                                                                                    L63P/  V82A or I54T: 10- to 
                                                                                                                                    20-fold; L24V/  G48V/  A71V/  
                                                                                                                                    V75I/  P81T: 1000-fold          (102, 103) 

  G 48 V    GGG to GTG        Protease Inhibitor        MP-167                 Y          ?   20            MP-134(5) SC-52151
                                                                                                            (16) Ro31-8959(5)  
                                                                                                            (Fold increase in 
                                                                                                            IC90s).                 L10F/G48V:20-fold               (119) 
 
  G 48 V    GGG to GTG        Protease Inhibitor        MK-639 (L-735,524,
                                                         Indinavir)            ?          Y    -                  -                         -                       (120) 

  I 50 V    ATT to GTT        Protease Inhibitor        VB 11,328              Y          ?    3                  -                 I50V/  M46I/  I47V: 
                                                                                                                                    20-fold                         (95) 

  I 50 V    ATT to GTT        Protease Inhibitor        VX-478 (141W94)        Y          ?    3                  -                        -                        (121) 

  I 54 M    ATT to ATG        Protease Inhibitor        BILA 2185 BS           Y          ?    -           BILA 1906 (360)          L10F/ L23I/ V32I/ M46I
                                                                                                                                    / I47V/ I54M/ A71V/ I84V:  
                                                                                                                                    1,500-fold.  Associated 
                                                                                                                                    Gag mutations:  p1/p6 
                                                                                                                                    cleavage site (L to F 
                                                                                                                                    (CTT to TTT at P1'); 
                                                                                                                                    p7/p1 cleavage site 
                                                                                                                                    (Q to R (CAG to CGG) at 
                                                                                                                                    P3'; A to V (GCT to CTT) 
                                                                                                                                    at P2'.                         (106) 

  I&54 V    ATC to GTC        Protease Inhibitor        ABT-538 (ritonavir)    N          Y    -                 -                  I54V/V82T: 9-fold; 
                                                                                                                                    K20R/M36I/I54V/V82A: 
                                                                                                                                    41-fold; M36I/I54V/A71V/
                                                                                                                                    V82T: 8-fold; I54V/A71V/
                                                                                                                                    V82A/L90N: 7-fold; In vivo, 
                                                                                                                                    V82A/F/T/S occurs first, 
                                                                                                                                    followed by changes at 
                                                                                                                                    54, 71 and 36                   (108) 

  I 54 V    ATC to GTC        Protease Inhibitor        MK-639 (L-735,524, 
                                                        indinavir)             ?          Y    -                 -                          -                       (112) 

  I 54 V    ATA to GTA        Protease Inhibitor        Ro 31-8959 
                                                        (saquinavir)           Y          -    -                 -                  In subtype O                      -

  I 54 V    ATC to GTC        Protease Inhibitor        Ro 31-8959 
                                                        (saquinavir)           Y          -    -                 -                  In subtype B                    (117, 118) 

  D 60 E    GAT to GAA        Protease Inhibitor        DMP 450                Y          ?    -                 -                  Probably compensatory           (97, 98) 

  L 63 P    CTC to CCC        Protease Inhibitor        MK-639 (L-735,524,
                                                         indinavir)            N          Y    -                 -                  M46I/  L63P/  V82T: 
                                                                                                                                    4-fold; L10R/  M46I/  
                                                                                                                                    L63P/  V82T/  I84V: 
                                                                                                                                    8-fold; L10R/  M46I/  
                                                                                                                                    L63P/  V82T: 4-fold             (105)  

  A 71 T    GCT to ACT        Protease Inhibitor        BMS 186,318            Y          ?    -                 -                  A71T/  V82A: 15-fold            (122, 123) 

  A 71 T    GCT to ACT        Protease Inhibitor        MK-639 (L-735,524,
                                                         indinavir)            ?          Y    -                 -                          -                       (105) 

  A 71 V         -            Protease Inhibitor        A-77003                Y          ?    -                 -                  V32I appears first; 
                                                                                                                                    progression to V32I/  
                                                                                                                                    M46V and V32I/  /  M46V/  
                                                                                                                                    A71V/  V82A occurs even 
                                                                                                                                    in the absence of drug; 
                                                                                                                                    M46I/  L63P/  A71V/  V82F/  
                                                                                                                                    I84V: 27-fold                   (95, 101) 

  A 71 V    GCT to GTT        Protease Inhibitor        ABT-538 (ritonavir)    Y          Y   -                 -                          -                        (108) 

  A 71 V    GCT to GTT        Protease Inhibitor        AG1343 (nelfinavir)    Y          ?   5                 -                   D30N/  A71V: 7-fold; 
                                                                                                                                    M46I/  L63P/  A71V/  
                                                                                                                                    I84V: 30-fold                     -

  A 71 V    GCT to GTT        Protease Inhibitor        BILA 1906 BS           Y          ?  -                  -                   V32I/  A71V: 3-fold; V32I/  
                                                                                                                                    M46I,L/ A71V/  I84V: 5-fold; 
                                                                                                                                    V32I/ M46I,L/ A71V/ I84A:  
                                                                                                                                    520-fold.  32I/ 46L/ 71V/ 
                                                                                                                                    84A are functionally impaired.  
                                                                                                                                    Associated Gag mutations:  
                                                                                                                                    p1/p6 cleavage site (L to F 
                                                                                                                                    (CTT to TTT at P1')             (106, 109, 112, 113) 

  A 71 V    GCT to GTT        Protease Inhibitor        BILA 2011 (palinavir)  Y          ? -              BILA 2185: 30-fold                -                      (112) 

  A 71 V    GCT to GTT        Protease Inhibitor        MK-639 (L-735,524,
                                                         indinavir)            Y          Y -                  -                   V32I/  M46L/  A71V/  V82A: 
                                                                                                                                   14-fold                          (95) 

  A 71 V    GCT to GTT        Protease Inhibitor        SC-52151               Y          ? -             Not L-735,524            A71V/  V75I/  P81T: 20- to 
m                                                                                                                                  30-fold; L24V/  G48V/  A71V/  
                                                                                                                                   V75I/  P81T: 1000-fold; N88D 
                                                                                                                                   or I11V/  M46I/  F53L/  A71V/  
                                                                                                                                   N88D:10- to 20-fold              (102, 103) 

  A 71 V    GCT to GTT        Protease Inhibitor        BILA 2185 BS           Y          ? -             BILA 1906 (360)          L10F/ L23I/ V32I/ M46I/ I47V/ 
                                                                                                                                   I54M/ A71V/ I84V:  1,500-fold.  
                                                                                                                                   Associated Gag mutations:  
                                                                                                                                   p1/p6 cleavage site (L to F 
                                                                                                                                   (CTT to TTT at P1'); p7/p1 
                                                                                                                                   cleavage site (Q to R 
                                                                                                                                   (CAG to CGG) at P3'; A to V 
                                                                                                                                   (GCT to CTT) at P2'.             (106) 

    G 73 S    GGT to GCT        Protease Inhibitor        MK-639 (L-735,524,
                                                         indinavir)            ?          Y -                                      Emerges following a switch 
                                                                                                                                   from saquinavir to indinavir.    (124) 
  
  V 75 I    GTA to ATA        Protease Inhibitor        SC-52151               Y          ? -                -                     L24V/  G48V/  A71V/  V75I/  
                                                                                                                                   P81T: 1000-fold; A71V/  V75I/  
                                                                                                                                   P81T: 20- to 30-fold; L24V/  
                                                                                                                                   G48V/  A71V/  V75I/  P81T: 
                                                                                                                                   1000-fold                        (102, 103) 

  V 77 I        -             Protease Inhibitor        AG1343 (nelfinavir)    Y          Y -                -                         -                               - 

  P 81 T    CCT to ACT        Protease Inhibitor        SC-52151               Y          ? -                -                     A71V/  V75I/  P81T: 20- to 
                                                                                                                                   30-fold; L24V/  G48V/  A71V/  
                                                                                                                                   V75I/  P81T: 1000-fold           (102, 103) 

  I 82 T    ATC to ACC        Protease Inhibitor        A-77003                Y          ? -                -                     G48V/  I82T: 100-fold 
                                                                                                                                   (82T was derived from in 
                                                                                                                                   vitro passage of 82I)            (125) 

  V 82 A    GTC to GCC        Protease Inhibitor        A-77003                Y          ? -                -                     Rare; seen with M46F; 
                                                                                                                                   V32I appears first; 
                                                                                                                                   progression to V32I/  M46V 
                                                                                                                                   and V32I/  /  M46V/  A71V/  
                                                                                                                                   V82A occurs even in the 
                                                                                                                                   absence of drug                 (95, 116, 125) 

  V 82 A    GTC to GCC        Protease Inhibitor        ABT-538 (ritonavir)    N          Y 2               -                      In vivo, V82 occurs first, 
                                                                                                                                   often followed by changes 
                                                                                                                                   at I54, A71 and M36             (108) 

  V 82 A    GTC to GCC        Protease Inhibitor        BMS 186,318            Y          ? -            A-77003 (4)               A71T/  V82A: 15-fold            (122, 123) 

  V 82 A    GTC to GCC        Protease Inhibitor        MK-639 (L-735,524,
                                                         indinavir)            Y          Y -              -                       V32I/  M46L/  V82A: 3-fold; 
                                                                                                                                   V32I/  M46L/  A71V/  V82A: 
                                                                                                                                   14-fold                         (105) 

  V 82 A    GTC to GCC        Protease Inhibitor        P9941                  Y          ? 6-8            -                               -                       (126) 

  V 82 A    GTC to GCC        Protease Inhibitor        SC-52151               Y          ? -              -                       G48V/  V82A, G48V/  L63P/  
                                                                                                                                   V82A or I54T: 10- to 
                                                                                                                                   20-fold                         -

  V 82 A         -            Protease Inhibitor        SKF108922              Y          ?               -                                -                       -  

  V 82 A    GTC to GCC        Protease Inhibitor        XM323                  Y          ? -             -                        V82A/  M46L: 7-fold; V82A/  
                                                                                                                                   M46L/  L97V: 11-fold; L10F/  
                                                                                                                                   V82A: 2-fold; ; V82A/  
                                                                                                                                   L97V: 3-fold                   (101) 

  V 82 A    GTC to GCC        Protease Inhibitor        Ro 31-8959 
                                                        (saquinavir)           ?          Y -             -                        Follows G48V during 
                                                                                                                                   saquinavir therapy or 
                                                                                                                                   after a switch to nelfinavir  
                                                                                                                                   or indinavir.                  (127, 128, 129) 
  
  V 82 F    GTC to TTC        Protease Inhibitor        ABT-538 (ritonavir)    Y          Y -             -                        V82F/  I84V: 8- to 10-fold; 
                                                                                                                                   M46I/  L63P/  A71V/  V82F/  
                                                                                                                                   I84V: 27-fold                  (108) 

  V 82 F    GTC to TTC        Protease Inhibitor        MK-639 (L-735,524,
                                                         indinavir)            ?          Y -             -                                -                      (99) 

  V 82 F    GTC to TTC        Protease Inhibitor        XM323                  Y          ? -             -                        V82F/  I84V: 92-fold           (101)  

  V 82 I    GTC to ATC        Protease Inhibitor        A-77003                Y          ? -             -                        No resistance alone but 
                                                                                                                                   V32I and V82I are synergistic 
                                                                                                                                   mutations yielding 20-fold 
                                                                                                                                   enzyme resistance (82T was 
                                                                                                                                   derived from in vitro passage 
                                                                                                                                   of 82I)                        (96) 

  V 82 I    GTC to ATC        Protease Inhibitor        XM323                  Y          ? <2            -                               -                       (101) 

  V 82 S    GTC to TCC        Protease Inhibitor        ABT-538 (ritonavir)    N          Y 6             -                        In vivo, V82 occurs first, 
                                                                                                                                   often followed by changes 
                                                                                                                                   at I54, A71 and M36            (108) 

  V 82 T    GTC to ACC        Protease Inhibitor        ABT-538 (ritonavir)    N          Y 3             -                        In vivo, V82 occurs first, 
                                                                                                                                   often followed by changes 
                                                                                                                                   at I54, A71 and M36; V82T 
                                                                                                                                   has reduced replication 
                                                                                                                                   efficacy in natural 
                                                                                                                                   background                     (108) 

  V 82 T    GTC to ACC        Protease Inhibitor        MK-639 (L-735,524,
                                                         indinavir)            N          Y -             -                        M46I/  L63P/  V82T: 4-fold; 
                                                                                                                                   L10R/  M46I/  L63P/  V82T: 
                                                                                                                                   4-fold; L10R/  M46I/  L63P/  
                                                                                                                                   V82T/  I84V: 8-fold            (105) 

  V 82 T         -            Protease Inhibitor        SKF108842              Y          ? -             -                                -                      (130) 

  V 82 T         -            Protease Inhibitor        SKF108922              Y          ? -             -                                -                      -

  I 84 A    ATA to GCA        Protease Inhibitor        BILA 1906 BS           Y          ? -       BILA 2185 BS (200)             V32I/  A71V: 3-fold; V32I/  
                                                                                                                                   M46I,L/ A71V/  I84V: 5-fold; 
                                                                                                                                   V32I/ M46I,L/ A71V/ I84A:  
                                                                                                                                   520-fold.  32I/ 46L/ 71V/ 
                                                                                                                                   84A are functionally 
 m                                                                                                                                 impaired.  Associated Gag 
                                                                                                                                   mutations:  p1/p6 cleavage 
                                                                                                                                   site (L to F (CTT to TTT 
                                                                                                                                   at P1')                        (106, 109, 112, 113) 

  I 84 A    ATG to ATA        Protease Inhibitor        BILA 2011 (palinavir)  Y          ? -       Ro 31-8959 (400);              I84A is the most 
                                                                                                                                   common mutation                (112) 

  I 84 V    ATA to GTA        Protease Inhibitor        ABT-538 (ritonavir)    Y          Y -            -                         M46I/  L63P/  A71V/  
                                                                                                                                   V82F/  I84V: 27-fold; 
                                                                                                                                   V82F/  I84V: 8- to 
                                                                                                                                   10-fold; M46I/  L63P/  
                                                                                                                                   A71V/  V82F/  I84V: 
                                                                                                                                   27-fold                        (108) 

  I 84 V    ATA to GTA        Protease Inhibitor        AG1343 (nelfinavir)    -          ? -            -                         M46I/  L63P/  A71V/  
                                                                                                                                   I84V: 30-fold                  (110) 

  I 84 V    ATA to GTA        Protease Inhibitor        BILA 1906 BS           Y          ? -       BILA 2185 BS(200)              V32I/  A71V: 3-fold; 
                                                                                                                                   V32I/  M46I,L / A71V/  
                                                                                                                                   I84V: 5-fold; V32I/ M46I,
                                                                                                                                   L/ A71V/ I84A:  520-fold.  
                                                                                                                                   32I/ 46L/ 71V/ 84A are 
                                                                                                                                   functionally impaired.  
                                                                                                                                   Associated Gag mutations:  
                                                                                                                                   p1/p6 cleavage site (L 
                                                                                                                                   to F (CTT to TTT at P1')       (106, 109, 112, 113) 

  I 84 V    ATA to GTA        Protease Inhibitor        BILA 2185 BS           Y          ? -      BILA 1906 BS(360)               L10F/ L23I/ V32I/ M46I/ 
                                                                                                                                   I47V/ I54M/ A71V/ I84V:  
                                                                                                                                   1,500-fold.  Associated 
                                                                                                                                   Gag mutations:  p1/p6 
                                                                                                                                   cleavage site (L to F 
                                                                                                                                   (CTT to TTT at P1'); 
                                                                                                                                   p7/p1 cleavage site 
                                                                                                                                   (Q to R (CAG to CGG) at 
                                                                                                                                   P3', A to V (GCT to CTT) 
                                                                                                                                   at P2'.                        (106) 

  I 84 V    ATA to GTA        Protease Inhibitor        DMP 450                Y          ? -            -                                     -                  (97, 98) 

  I 84 V    ATA to CTA        Protease Inhibitor        MK-639 (L-735,524,
                                                         indinavir)            N          Y -            -                         G48V/  I84V/  L90M: 30-fold; 
                                                                                                                                   L10R/  M46I/  L63P/  V82T/  
                                                                                                                                   I84V: 8-fold                   (105) 

  I 84 V    ATA to GTA        Protease Inhibitor        Ro 31-8959 
                                                        (saquinavir)           Y          ? -            -                                     -              (95) 

  I 84 V    ATA to GTA        Protease Inhibitor        RPI-312                Y          ? 5            -                                     -              (131) 

  I 84 V         -            Protease Inhibitor        SKF108842              Y          ? -            -                                     -                - 

  I 84 V    ATA to GTA        Protease Inhibitor        VB 11,328              Y          ? -            -                         L10F/  I84V: 8-fold          -

  I 84 V    ATA to GTA        Protease Inhibitor        VX-478 (141W94)        Y          ? -            -                                     -                - 

  I 84 V    ATA to GTA        Protease Inhibitor        XM323                  Y          ? 12     P9941; not A-77003 
                                                                                                   or Ro 31-8959                  V82F/  I84V: 92-fold;L10F/  
                                                                                                                                  K45I/  I84V:50-fold         (95, 101) 

  I 84 V    ATA to GTA        Protease Inhibitor        MP-134                 Y          ? 10     MP-167(5) ABT-
                                                                                                   538(10) MK-639(8) 
                                                                                                   SC-52151(8) Ro31-895(2) 
                                                                                                   (IC90 data)                               -                (132) 

  N 88 D         -            Protease Inhibitor        AG1343 (nelfinavir)    Y          Y -           -                         D30N and N88D are most 
                                                                                                                                  common in vivo after 24 
                                                                                                                                  weeks of therapy; they 
                                                                                                                                  do not cause cross-
                                                                                                                                  resistance to other 
                                                                                                                                  protease inhibitors         (110) 

  N 88 D    AAT to GAT        Protease Inhibitor        SC-52151               Y          ? -           -                         N88D compensatory, 
                                                                                                                                  no resistance alone         (132) 

  N 88 S    AAT to AGT        Protease Inhibitor        SC-55389A              Y          ? 20    L735,524 (3); 
                                                                                                  not SC-52151                    N88S/L10F:  25              (104) 

  L 90 M    TTG to ATG        Protease Inhibitor        ABT-538 (ritonavir)    N          Y -           -                         82A/   54V/  I/   71V/   
                                                                                                                                  90L/  M: 7-fold             (108) 

  L 90 M    TTG to ATG        Protease Inhibitor        AG1343 (nelfinavir)    N          Y -           -                         Rare in patients            (110) 

  L 90 M    TTG to ATG        Protease Inhibitor        MK-639 (L-735,524,
                                                         indinavir)            ?          Y -           -                                   -                 (105) 

  L 90 M    TTG to ATG        Protease Inhibitor        Ro 31-8959 
                                                        (saquinavir)           Y          Y -           -                         G48V/  L90M: >100-fold 
                                                                                                                                  enzyme resistance; double 
                                                                                                                                  mutant rare in vivo; L90M 
                                                                                                                                  most common in vivo; 
                                                                                                                                  G48V/  I84V/  L90M: 
                                                                                                                                  30-fold                     (117) 

  L 97 V    TTA to GTA        Protease Inhibitor        XM323                  Y          ? -           -                         No resistance alone;
                                                                                                                                  V82A/L97V: 3-fold; 
                                                                                                                                  V82A/  M46L/  L97V: 
                                                                                                                                  11-fold                     (101)
</pre>
<strong>Mutations in Envelope and Drug Resistance</strong>
<pre>
Amino Acid    Codon            Class of Drug                    Compound      In         In       -Fold      Cross-resistace         comments                Refs
  Change     channge                                                         vitro      Vivo   -resistance        (-fold)

  R 22 A    AGG to AGA         Fusion/ Binding Inhibitor     RPR103611         Y          ?         -              -                     -                    (132)

  I 84 S    ATC to AGC         Fusion/ Binding Inhibitor     RPR103611         Y          ?         -              -                     -                    (132) 

  S 113 N   AGT to AAT         Fusion/  Binding Inhibitor    Dextran sulphate 
                                                                (DS)           Y          ?         -              -            S113N/  S134N/  K269E/  
                                                                                                                                Q278E/  N293D/  
                                                                                                                                N323S/  R387I: 250-fold; 
                                                                                                                                113 is in the V1 loop region (132, 133)

  S 134 N   AGC to AAC         Fusion/  Binding Inhibitor    Dextran sulphate 
                                                                (DS)           Y         ?          -              -            V2 loop region; S113N/  
                                                                                                                                S134N/  K269E/  
                                                                                                                                Q278E/  N293D/  N323S/  
                                                                                                                                R387I: 250-fold               (133, 134)

  F 145 L   TTC to TTA         Fusion/  Binding Inhibitor    JM-3100           Y         ?          -              -            Combination of mutations: 
                                                                                                                                2- to 100-fold                (135, 136) 

  N 188 K   AAT to AAA         Fusion/  Binding Inhibitor    Siamycin I        Y         ?          -              -            N188K/  G332E/  N351D/  
                                                                                                                                A550T/  N633D/  L762S: 
                                                                                                                                 9-fold                       (137)

  I 228 V   ATA to GTA         Fusion/  Binding Inhibitor    JM-2763           Y         ?          -              -            Combination of mutations          -

  K 269 E   AAA to GAA         Fusion/  Binding Inhibitor    Dextran sulphate 
                                                                (DS)           Y         ?          -              -            V3 loop region; S113N/  
                                                                                                                                S134N/  K269E/  
                                                                                                                                Q278E/  N293D/  N323S/  
                                                                                                                                R387I: 250-fold               (133, 134)

  N 270 S   AAT to AGT         Fusion/  Binding Inhibitor    JM-3100           Y         ?          -              -                      -                      - 

  R 272 T   AGA to ACA Fusion/  Binding Inhibitor            JM-3100           Y         ?          -              -                      -                      -                       

  S 274 R   AGT to AGA Fusion/  Binding Inhibitor            JM-2763           Y         ?          -              -            Combination of mutations: 
                                                                                                                                95- to 792-fold                (135, 136) 

  S 274 R   AGT to AGA Fusion/  Binding Inhibitor            JM-3100           Y         ?    DS (> 7 to 6,667)    -                

  Q 278 H   CAG to CAT Fusion/  Binding Inhibitor            Dextran sulphate 
                                                             (DS)              Y         ?          -              -            V3 loop region; S113N/  
                                                                                                                                S134N/  K269E/  
                                                                                                                                Q 278E/   N293D/  N323S/  
                                                                                                                                R387I: 250-fold                (133, 134)

  Q 278 H   CAG to CAT Fusion/  Binding Inhibitor            JM-2763           Y         ?          -              -                     -

  Q 278 H   CAG to CAC Fusion/  Binding Inhibitor            JM-3100           Y         ?          -              -                     - 

  I 288 V   ATA to GTA Fusion/  Binding Inhibitor            JM-3100           Y         ?          -              -                     - 

  N 293 D   AAT to GAT Fusion/  Binding Inhibitor            Dextran sulphate 
                                                             (DS)              Y         ?          -              -           V3 loop region; S113N/  
                                                                                                                               S134N/  K269E/  Q278E/  
                                                                                                                               N293D/  N323S/  R387I: 
                                                                                                                               250-fold                       (133, 134) 

  N 293 H  AAT to CAT Fusion/  Binding Inhibitor             JM-3100           Y         ?          -               -                   - 

  A 297 T  GCA to ACA Fusion/  Binding Inhibitor             JM-2763           Y         ?          -               -                   -                        -

  A 297 T  GCA to ACA Fusion/  Binding Inhibitor             JM-3100           Y         ?          -               -                   -                        - 

  N 323 S  AAT to AGT Fusion/  Binding Inhibitor             Dextran sulphate 
                                                             (DS)              Y         ?          -               -          C3 region; S113N/  
                                                                                                                               S134N/  K269E/  Q278E/  
                                                                                                                               N293D/  N323S/  R387I: 
                                                                                                                               250-fold                       (133, 134)

  G 332 E  GGA to GAA Fusion/  Binding Inhibitor             Siamycin I        Y         ?          -               -          N188K/  G332E/  N351D/  
                                                                                                                               A550T/  N633D/  L762S: 
                                                                                                                               9-fold                         (137) 

  N 351 D  AAT to GAT Fusion/  Binding Inhibitor             Siamycin I        Y         ?          -               -          N188K/  G332E/  N351D/  
                                                                                                                               A550T/  N633D/  L762S: 
                                                                                                                               9-fold                         (137) 

  P 385 L  CCA to CTA Fusion/  Binding Inhibitor             JM-2763           Y         ?          -               -                   -

  P 385 L  CCA to CTA Fusion/  Binding Inhibitor             JM-3100           Y         ?          -               -                   -

  R 387 I  AGA to ACA Fusion/  Binding Inhibitor            Dextran sulphate 
                                                            (DS)               Y         ?          -               -          CD4 binding region; 
                                                                                                                               S113N/  S134N/  K269E/  
                                                                                                                               Q278E/  N293D/  N323S/  
                                                                                                                               R387I: 250-fold               (133, 134)

  Q 410 E  CAA to GAA Fusion/  Binding Inhibitor            JM-3100            Y         ?          -               -                   - 

  S 433 P  TCC to CCC Fusion/  Binding Inhibitor            JM-3100            Y         ?          -               -                   - 

  V 457 I  GTA to ATA Fusion/  Binding Inhibitor            JM-3100            Y         ?          -               -                   -

  A 550 T  GCC to ACC Fusion/  Binding Inhibitor            Siamycin I         Y         ?          -               -          N188K/  G332E/  N351D/  
                                                                                                                               A550T/  N633D/  L762S: 
                                                                                                                               9-fold                         (137) 

  N 633 D  AAT to GAT Fusion/  Binding Inhibitor            Siamycin I         Y         ?          -               -          N188K/  G332E/  N351D/  
                                                                                                                               A550T/  N633D/  L762S: 
                                                                                                                               9-fold                         (137) 

  L 762 S  TTG to TCG Fusion/  Binding Inhibitor            Siamycin I         Y         ?          -               -          N188K/  G332E/  N351D/  
                                                                                                                               A550T/  N633D/  L762S: 
                                                                                                                               9-fold                         (137) 

</pre>
<strong>Mutations in SIV Reverse Transccriptase and Drug Resistance</strong>
<pre>
Amino Acid    Codon            Class of Drug                    Compound      In         In       -Fold      Cross-resistace                 comments                        Refs
  Change     channge                                                         vitro      Vivo   -resistance        (-fold)

  K 65 R    AAA to AGA        SIV Nucleoside RT Inhibitor        PMPA          ?          Y         5        3TC (80); ddI; ddC; d4T;  K65R appears first, followed by       (138, 139, 140)
                                                                                                                     PMEA              N69S and I118V. Observed changes 
                                                                                                                                       at N69S and I118V do not result 
                                                                                                                                       in increased resistance.

  Q 151 M   CAG to ATG        SIV Nucleoside RT Inhibitor         AZT          ?          Y        >100       ddI; ddC; d4T; 3TC                 -                           (141)

  M 184 V   ATG to GTG        SIV Nucleoside RT Inhibitor       (-)-FTC        Y          ?         -              -                             -                           (82)
</pre>
<strong>Mutations in FIV Reverse Transcriptase and Drug Resistance</strong>
<pre>
Amino Acid    Codon            Class of Drug                    Compound      In         In       -Fold       Cross-resistace                comments                         Refs
  Change     channge                                                         vitro      Vivo   -resistance        (-fold)

  L 74  I   TTA to ATA        HIV-1 Specific RTI                 HBY 097       Y          ?         -                -                          -                             (16)

  D 3   H   GAT to CAT        FIV Nucleoside RT Inhibitor          ddC         Y          ?         4            ddI; PFA                       -                             (142, 143)
  
  V 47  I   GTA to ATA        FIV Nucleoside RT Inhibitor          d4T         Y          ?        4-6      PFA (>50); AZT; ddI; PMEA           -                             (144)

  P 156 S   CCA to TCA        FIV Nucleoside RT Inhibitor          3TC         Y          ?         7       AZT (4), AZT + 3TC (6)              -                             (145)

  M 183 T   ATG to ACG        FIV Nucleoside RT Inhibitor        (-)-FTC       Y          ?        10             ddC                   Corresponds to 184 in HIV; M183V      (146)
                                                                                                                                        recombinant displays 10-fold 
                                                                                                                                        resistance to 3TC or (-)-FTC.
</pre>
<strong>Abbreviations</strong>
<p>
<strong>Amino acids</strong>
<pre>
     A                       alanine
     C                       cysteine
     D                       aspartate
     E                       glutamate
     F                       phenyalanine
     G                       glycine
     H                       histidine
     I                       isoleucine
     K                       lysine
     L                       leucine
     M                       methionine
     N                       asparagine
     P                       proline
     Q                       glutamine
     R                       arginine
     S                       serine
     T                       threonine
     V                       valine
     W                       tryptophan
     Y                       tyrosine
</pre>
<strong>Compounds</strong>
<pre>
     1592U89             (1S,4R)-4-[2-amino-6-cyclopropyl-amino)-9H-purin-9-yl]-2-cyclopentene-1-methanol succinate (a carbovir analogue, Glaxo Wellcome)
     3TC                 (-)-§-L-2',3'-dideoxy-3'-thiacytidine (Glaxo Wellcome)
     1737                Tetrahydronapthalene lignan derivative
     Ï-APA R18893        Ï-nitro-anilino-phenylacetamide
     A-77003, A-75925    C2 symmetry-based protease inhibitors (Abbott Laboratories)
        and A-80987
     AAP-BHAP            bisheteroarylpiperazine analogue (Pharmacia & Upjohn)
     ABT-538             C2 symmetry-based protease inhibitor (Abbott Laboratories)
     AZdU                3'-azido-2',3'-dideoxyuridine
     AZT                 3'-azido-3'-deoxythymidine (Glaxo Wellcome)
     AZT-p-ddI           3'-azido-3'-deoxythymidilyl-(5',5')-2',3'-dideoxyinosinic acid (Ivax)
     BHAP                bisheteroarylpiperazine
     BILA 1906           N-1S-[[[3-[2S-(1,1-dimethylethyl)amino]carbonyl-4R-]3-pyridinylmethyl)thio]-1-piperidinyl]-2R-hydroxy-1S-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl}-2-quinolinecarboxamide (Bio-Mega/Boehringer Ingelheim)
     BILA 2185           N-(1,1-dimethylethyl)-1-[2S-[[2-2,6-dimethyphenoxy)-1-oxoethyl]amino]-2R-hydroxy-4-phenylbutyl]4R-pyridinylthio)-2-piperidine-carboxamide (Bio-Mega/Boehringer Ingelheim)
     BM+51.0836          thiazolo-isoindolinone derivative
     BMS 186,318         aminodiol derivative HIV-1 protease inhibitor (Bristol-Myers Squibb)
     d4API               9-[2,5-dihydro-5-(phosphonomethoxy)-2-furanel]adenine (Gilead Sciences)
     d4C                 2',3'-didehydro-2',3'-dideoxycytidine
     d4T                 2',3'-didehydro-3'-deoxythymidine (Bristol-Myers Squibb)
     ddC                 2',3'-dideoxycytidine (Roche)
     ddI                 2',3'-dideoxyinosine (Bristol-Myers Squibb)
     DMP 266             a 1,4-dihydro-2H-3,1-benzoxazin-2-one
     DMP 450             [4R-(4-Ï,5-Ï,6-§,7-§)]-hexahydro-5,6-bis(hydroxy)-1,3-bis(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2H-1,3-diazepin-2-one-bismesylate (Avid Therapeutics)
     DXG                 (-)-§-D-dioxolane-guanosine
     EBU-dM              5-ethyl-1-ethoxymethyl-6-(3,5-dimethylbenzyl)uracil
     E-EBU               5-ethyl-1-ethoxymethyl-6-benzyluracil
     DS                  dextran sulphate
     E-EPSeU             1-(ethoxymethyl)-(6-phenylselenyl)-5-ethyluracil
     E-EPU               1-(ethoxymethyl)-(6-phenyl-thio)-5-ethyluracil
     F-ddA               2'-fluoro-2',3'-dideoxyadenosine
     (-)-FTC             (-)-§-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine (Triangle Pharmaceuticals)
     HBY 097             (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthio-methyl)-3,4-dihydroquinoxalin-2(1H)-thione
     HEPT                1-[(2-hydroxyethoxy)methyl]6-(phenylthio)thymine
     JM2763              1,1'-(1,3-propanediyl)-bis-1,4,8,11-tetraazacyclo-tetradecane (Johnson Matthey)
     JM3100              1,1'-[1,4-phenylenebis-(methylene)]bis-(1,4,8,11-tetra\-azacyclo\-tetra\-decane) octa\-hydro\-chloride dihydrate (Johnson Matthey)
     KNI-272             (2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acid-containing tripeptide
     L-697,593           5-ethyl-6-methyl-3-(2-phthalimido-ethyl)pyridin-2(1H)-one
     L-697,661           3-[(-4,7-dichloro-1,3-benzoxazol-2-yl)methyl]amino-5-ethyl-6-methylpyridin-2(1H)-one
     L-FDDC              (-)-§-L-5-fluoro-2',3'-dideoxy-cytidine
     L-FDOC              (-)-§-L-5-fluoro-dioxolane cytosine
     MK-639              hydroxy-aminopentane amide HIV-1 protease inhibitor (Merck \              Co)
     MKC442              6-benzyl-1-ethoxymethyl-5-isopropyluracil (I-EBU, Triangle Pharmaceuticals/Mitsubishi)
     MP-134              C2 symmetry-based protease inhibitor
     MP-167              C2 symmetry-based protease inhibitor	
     nevirapine          11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyridol[3,2-b:2',3'-e] diazepin-6-one (Boehringer Ingelheim)
     NNRTI               non-nucleoside reverse transcriptase inhibitor
     NSC648400           1-benzyloxymethyl-5-ethyl-6-(Ï-pyridylthio)uracil (E-BPTU)
     P9941               [2-pyridylacetyl-IIePheAla-y(CHOH)]\sub2 (Dupont Merck)
     PFA                 phosphonoformate (foscarnet, Astra)
     PMEA                9-(2 phosphonylmethoxyethyl)adenine (Gilead Sciences)
     PMPA                (R)-9-(2-phosphonyl-methoxypropyl)adenine (Gilead Sciences)
     Ro 31-8959          hydroxyethylamine derivative HIV-1 protease inhibitor (Roche)
     RPI-312             1-[(3S)-3-(n-Ï-benzyloxycarbonyl)-l-asparginyl)-amino-2-hydroxy-4-phenyl-butyryl]-n-tert-butyl-l-proline amide (peptidyl protease inhibitor)
     RPR103611
     RT                  reverse transcriptase
     S-2720              6-chloro-3,3-dimethyl-4-(isopropenyl-oxycarbonyl)-3,4-dihydro-quinoxalin-2(1H)thione
     SC-52151            hydroxyethylurea isostere protease inhibitor (Searle)
     SC-55389A           hydroxyethyl-urea isostere protease inhibitor (Searle)
     TIBO R82150         (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thione (Janssen)
     TIBO 82913          (+)-(5S)-4,5,6,7,-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)-imidazo-[4,5,1-jk]-[1,4]benzo-diazepin-2(1it\ H)-thione (Janssen)
     TSAO-m$^3$T         [2',5'-bis-O-(tert-butyl-dimethylsilyl)-3'-spiro-5'-(4'-amino-1',2'-oxathiole-2',2'-dioxide)]-§-D-pentofuranosyl-N$^3$-methylthymine
     U-90152             1-[3-[(1-methylethyl)-amino]-2-pyridinyl]-4-[[5-[(methylsulphonyl)-amino]-lH-indol-2yl]carbonyl]-piperazine
     U-95133             (Alkylamino)piperidine bis(heteroaryl)piperizine analog
     U-104489            (Alkylamino)piperidine bis(heteroaryl)piperizine analog
     UC-040              thiocarboxanilide derivative (Uniroyal Chemical Co)
     UC                  thiocarboxanilide derivatives (Uniroyal Chemical Co)
     UC-781              N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-furan-carbothioamide
     UC-82               N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-thiophene-carbothioamide
     VB 11,328           hydroxyethyl-sulphonamide protease inhibitor (Vertex Pharmaceuticals)
     VX-478              hydroxyethylsulphonamide protease inhibitor (Vertex Pharmaceuticals)
     XM 323              cyclic urea protease inhibitor (Dupont Merck)
</pre>
<strong>References</strong>
<p>
<strong>1. </strong>Larder BA and Kemp SD. Multiple mutations in HIV-1 reverse transcriptase
confer high-level resistance to zidovudine (AZT). <i>Science</i> 1989; <strong>
246</strong>:1155-1158.<p>
<strong>2. </strong>Larder BA, Coates KE and Kemp SD. Zidovudine-resistant
human immunodeficiency virus selected by passage in cell culture. <i>Journal of
Virology</i> 1991; <strong> 65</strong>(10):5232-5236.<p>
<strong>3. </strong>Kellam P, Boucher CA and Larder
BA. Fifth mutation in human immunodeficiency virus type 1 reverse
transcriptase contributes to the development of high-level resistance to
zidovudine. <i>Proceedings of the National Academy of Sciences, USA</i> 1992; <strong>
89</strong>(5):1934-1938.<p>
<strong>4. </strong>Iversen AK, Shafer RW, Wehrly K, Winters MA,
Mullins JI, Chesebro B and Merigan TC. Multidrug-resistant human
immunodeficiency virus type 1 strains resulting from combination
antiretroviral therapy. <i>Journal of Virology</i> 1996; <strong> 70</strong>(2):1086-1090.<p>
<strong>5. </strong>Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML,
Chokekijchai S, Roy BM, Arnold E, Yarchoan R and Mitsuya H. Emergence of human
immunodeficiency virus type 1 variants with resistance to multiple
dideoxynucleosides in patients receiving therapy with dideoxynucleosides.
<i>Proceedings of the National Academy of Sciences, USA</i> 1995; <strong> 92</strong>:1-5.<p>
<strong>6. </strong>Zhang D, Caliendo AM, Eron JJ,
DeVore KM, Kaplan JC, Hirsch MS and D'Aquila RT. Resistance to
2',3'-dideoxycytidine conferred by a mutation in codon 65
of the human immunodeficiency virus type 1 reverse transcriptase.
<i>Antimicrobial Agents and Chemotherapy</i> 1994; <strong> 38</strong>(2):282-287.<p>
<strong>7. </strong>Gu Z,
Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron JM and Wainberg MA.
Identification of a mutation at codon 65 in the IKKK motif of reverse
transcriptase that encodes human immunodeficiency virus resistance to
2',3'-dideoxycytidine and
2',3'-dideoxy-3'-thiacytidine. <i>Antimicrobial
Agents and Chemotherapy</i> 1994; <strong> 38</strong>(2):275-281.<p>
<strong>8. </strong>Tisdale M, Alnadaf T, Cousens D.  Combination of mutations in human
immunodeficiency virus type 1 reverse transcriptase required for resistance to the
carbocyclic nucleoside 1592U89.  <i>Antimicrobial Agents and Chemotherapy</i> 1997;
<strong>41</strong>(5):1094-1098.<p>
<strong>9. </strong>Mellors JW, Bazmi H, Chu
CK and Schinazi RF. K65R mutation in HIV-1 reverse transcriptase causes
resistance to (-)-§-D-dioxolane-guanine and reverses AZT resistance.
Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, 3-6
July, 1996. Abstract 7.<p>
<strong>10. </strong>Gu Z, Salomon H,
Cherrington JM, Mulato AS, Chen MS, Yarchoan R, Foli A, Sogocio KM and
Wainberg MA. K65R mutation of human immunodeficiency virus type 1 reverse
transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.
<i>Antimicrobial Agents and Chemotherapy</i> 1995; <strong> 39</strong>(8):1888-1891.<p>
<strong>11. </strong>Foli A, Sogocio KM, Anderson B, Kavlick M,
Saville MW, Wainberg MA, Gu X, Cherrington J, Mitsuya H and Yarchoan R. In
vitro selection and molecular characterization of human immunodeficiency virus
type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy-ethyl]adenine
(PMEA). <i>Antiviral Research</i> 1996; <strong> 32</strong>(2):  91-98.<p>
<strong>12. </strong>Cherrington JM, Chandok R, Mulato AS, Lamy PD, Mitsuya H, Wainberg M.  In vitro
selection and characterization of HIV-1 variants with reduced susceptibility to
PMPA.  <i>6th International Workshop on HIV Drug Resistance, 25-28 June 1997; St.
Petersburg, USA</strong>:  Abstract 26.<p>
<strong>13. </strong>Fitzgibbon JE, Howell RM, Haberzettl CA, Sperber SJ, Gockle DJ and Dubin
DT. Human immunodeficiency virus type 1 pol gene mutations which cause
decreased susceptibility to 2',3'-dideoxycytidine.
<i>Antimicrobial Agents and Chemotherapy</i> 1992; <strong> 36</strong>:153-157.<p>
<strong>14. </strong>Cherrington J, Mulato AS, Fuller MD and Chen MS. A novel mutation (K70E) in
HIV-1 reverse transcriptase confers decreased susceptibility to
9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) in vitro. <i>Antimicrobial Agents and
Chemotherapy</i> 1996; 40(9):  <strong> 22</strong>12-2216.<p>
<strong>15. </strong>Mulato AS, Lamy PL, Li W, Miller MD, Cherrington JM.  Genotypic characterization
of HIV-1 variants isolated from AIDS patients treated with adefovir dipivoxil
(bis-POM PMEA).  <i>6th Internation Workshop on HIV Drug Resistance, 25-28 June
1997; St. Petersburg, USA</strong>:  Abstract 24.<p>
<strong>16. </strong>Kleim JP, Rosner M,
Winkler I, Paessens A, Kirsch R, Hsiou Y, Arnold E and Riess G. Selective
pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency
virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results
in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74 to Val or Ile
and Val-75 to Leu or Ile) HIV-1 mutants. <i>Proceedings of the National Academy of
Sciences, USA</i> 1996; <strong> 93</strong>(1):34-38.<p>
<strong>17. </strong>St Clair MH, Martin JL, Tudor-Williams G, Bach
MC, Vavro CL, King DM, Kellam P, Kemp SD and Larder BA. Resistance to ddI and
sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. <i>Science</i> 1991; <strong> 253</strong>:1557-1559.<p>
<strong>18. </strong>Lacey SF and Larder BA. Novel
mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase
confers resistance to
2',3'-didehydro-2',3'-dideoxythymidine
in cell culture. <i>Antimicrobial Agents and Chemotherapy</i> 1994; <strong>
38</strong>(6):1428-1432.<p>
<strong>19. </strong>Schinazi RF, Stuyver L, Wyseur A, Lloyd RM Jr, Hough
L, Rombout A, Rossau R, and Rimland D. Proviral and plasma virus genotyping
using a line probe assay in nucleoside treated HIV infected Veterans Affairs
patients. Fifth International Workshop on HIV Drug Resistance, Whistler,
Canada, 3-6 July, 1996. Abstract 65.<p>
<strong>20. </strong>Mellors J, Bazmi H, Schinazi RF,
Roy B, Hsiou Y, Arnold E, Weir J and Mayers D. Novel mutations in the reverse
transcriptase of human immunodeficiency virus type 1 reduce susceptibility to
foscarnet in laboratory and clinical isolates. <i>Antimicrobial Agents and
Chemotherapy</i> 1995; <strong> 39</strong>(5):1087-1092.<p>
<strong>21. </strong>Tachedjian G, Hooker DJ,
Gurusinghe AD, Bazmi H, Deacon NJ, Mellors J, Birch C and Mills J.
Characterisation of foscarnet-resistant strains of human immunodeficiency
virus type 1. <i>Virology</i> 1995; <strong> 212</strong>(1):58-68.<p>
<strong>22. </strong>Tachedjian G, Mellors
J, Bazmi H, Birch C and Mills J. Zidovudine resistance is suppressed by
mutations conferring resistance of human immunodeficiency virus type 1 to
foscarnet. <i>Journal of Virology</i> 1996; <strong> 70</strong>:7171-7181.<p>
<strong>23. </strong>Prasad VR, Lowy I, de
los Santos T, Chiang L and Goff SP. Isolation and characterization of a
dideoxyguanosine triphosphate-resistant mutant of human immunodeficiency virus
reverse transcriptase. <i>Proceedings of the National Academy of Sciences, USA</i>
1991; <strong> 88</strong>(24):11363-11367.<p>
<strong>24. </strong>Byrnes VW, Sardana VV, Schleif WA,
Condra JH, Waterbury JA, Wolfgang JA, Long WJ, Schneider CL, Schlabach AJ,
Wolanski BS, Graham DJ, Gotlib L, Rhodes A, Titus DL, Roth E, Blahy OM,
Quintero JC, Staszewski S and Emini EA. Comprehensive mutant enzyme and viral
variant assessment of human immunodeficiency virus type 1 reverse
transcriptase resistance to nonnucleoside inhibitors. <i>Antimicrobial Agents and
Chemotherapy</i> 1993; <strong> 37</strong>(8):1576-1579.<p>
<strong>25. </strong>Richman DD, Havlir D, Corbeil
J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K,
Pauletti D, Shih CK, Myers M and Griffin J. Nevirapine resistance mutations of
human immunodeficiency virus type 1 selected during therapy. <i>Journal of
Virology</i> 1994; <strong> 68</strong>(3):1660-1666.<p>
<strong>26. </strong>Mellors JW, Im GJ, Tramontano E, Winkler SR, Medina DJ, Dutschman GE, Bazmi
HZ, Piras G, Gonzalez CJ and Cheng YC. A single conservative amino acid
substitution in the reverse transcriptase of human immunodeficiency virus-1
reverse transcriptase confers resistance to TIBO R82150. <i>Molecular
Pharmacology</i> 1993; <strong> 43</strong>(1):11-16.<p>
<strong>27. </strong>Balzarini J, Karlsson A,
Perez-Perez MJ, Vrang L, Walbers J, Zhang H, Oberg B, Vandamme AM, Camarasa MJ
and De Clercq E. HIV-1 specific reverse transcriptase inhibitors show
differential activity against HIV-1 mutant strains containing different amino
acid substitutions in the reverse transcriptase. <i>Virology</i> 1993; <strong>
192</strong>:246-253.<p>
<strong>28. </strong>Byrnes V, Blahy O, Condra J, Gotlib L, Graham D, Long W,
Quintero J, Rhodes A, Roth E, Sardana V, Schlabach A, Schleif W, Schneider C,
Titus D, Wolanski B, Wolfgang J and Emini E. Phenotypic susceptibility of
human immunodeficiency virus type 1 RT containing substitutions which engender
resistance to nucleoside and non-nucleoside inhibitors. Third Workshop on
Viral Resistance, 1993, Gaithersburg, MD, USA.<p>
<strong>29. </strong>Larder, BA.
3'-Azido-3'-deoxythymidine resistance suppressed by a
mutation conferring human immunodeficiency virus type 1 resistance to
nonnucleoside reverse transcriptase inhibitors. <i>Antimicrobial Agents and
Chemotherapy</i> 1992; <strong> 36</strong>(12):2664-2669.<p>
<strong>30. </strong>Richman DD. Resistance of
clinical isolates of human immunodeficiency virus to antiretroviral agents.
<i>Antimicrobial Agents and Chemotherapy</i> 1993; <strong> 37</strong>(6):1207-1213.<p>
<strong>31. </strong>Winslow DL, Garber S, Reid C, Scarnati H, Baker D, Rayner, MM, Anton ED. 
Selection conditions affect the evolution of specific mutations in the reverse
transcriptase gene associated with resistance to DMP 266.  {AIDS </strong>1996;
<strong>10</strong>(11):1205-1209.<p>
<strong>32. </strong>Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA,
Anderson JR, Huff PS, Olsen DB, Carroll SS, Pettibone DJ, O'Brien JA, Ball RG,
Balani SK, Lin JH, Chen IW, Schleif WA, Sardana VV, Long WJ, Byrenes VW and Emini
EA. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human
immunodeficiency virus type 1 reverse transcriptase. <i>Antimicrobial Agents and
Chemotherapy</i> 1995; <strong> 39</strong>(12):2602-2609.<p>
<strong>33. </strong>Balzarini J, Karlsson A,
Perez-Perez MJ, Camarasa MJ, Tarpley WG and De Clercq E. Treatment of human
immunodeficiency virus type 1 (HIV-1)-infected cells by combinations of
HIV-1-specific inhibitors results in a different resistance pattern than does
treatment with single-drug therapy. <i>Journal of Virology</i> 1993; <strong>
67</strong>(9):5353-5359.<p>
<strong>34. </strong>Vasudevachari MB, Battista C, Lane HC, Psallidopoulos
MC, Zhao B, Cook J, Palmer JR, Romero DL, Tarpley WG and Salzman NP.
Prevention of the spread of HIV-1 infection with nonnucleoside reverse
transcriptase inhibitors. <i>Virology</i> 1992; <strong> 190</strong>(1):269-2977.<p>
<strong>35. </strong>Balzarini J, Perez-Perez MJ,
Velazquez S, San-Felix A, Camarasa MJ, De Clercq E and Karlsson A. Suppression
of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell
culture by thiocarboxanilide derivatives when used individually or in
combination with other HIV-1-specific inhibitors (ie, TSAO derivatives).
<i>Proceedings of the National Academy of Sciences, USA</i> 1995; <strong>
92</strong>:5470-5474.<p>
<strong>36. </strong>Buckheit RW, Kinjerski TL, Fliakas-Boltz V, Russell JD,
Stup TL, Pallansch LA, Brouwer WG, Dao DC, Harrison WA, Schultz RJ, Bader JP
and Yang SS. Structure-activity and cross-resistance evaluations of a series
of human immunodeficiency virus type 1-specific compounds related to oxathiin
carboxanilide. <i>Antimicrobial Agents and Chemotherapy</i> 1995; <strong>
39</strong>(12):2718-2727.<p>
<strong>37. </strong>Balzarini J, Pelemans H, Aquaro S, Perno CF,
Witvrouw M, Schols D, De Clercq E and Karlsson A. Highly favourable antiviral
activity and resistance profile of the novel thiocarboxanilide pentenyloxy
ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency
virus type 1 (HIV-1) replication. <i>Molecular Pharmacology</i> 1996; <strong> 50</strong>(2): 394-410.<p>
<strong>38. </strong>Balzarini J, Brouwer WG, Dao DC, Osika EM and De Clercq E. Identification
of novel thiocarboxanilide derivatives that suppress a variety of
drug-resistant mutant human immunodeficiency virus type 1 strains at a potency
similar to that for wild-type virus. <i>Antimicrobial Agents and Chemotherapy</i>
1996; <strong> 40</strong>(6):1454-1466.<p>
<strong>39. </strong>Buckheit RW Jr, Fliakas-Boltz V, Decker
WD, Roberson JL, Stup TL, Pyle CA, White EL, McMahon JB, Currens MJ, Boyd MR
and Bader JP. Comparative anti-HIV evaluation of diverse HIV-1-specific
reverse transcriptase inhibitor-resistant virus isolates demonstrates the
existence of distinct phenotypic subgroups. <i>Antiviral Research</i> 1995; <strong>
26</strong>:117-132.<p>
<strong>40. </strong>Moeremans M, De Raeymaeker M, Van den Broeck R, Stoffels
P, De Brabander M, De Cree J, Hertogs K, Pauwels R, Staszewski S and Andries
K. Virological analysis of HIV-1 isolates in patients treated with the
non-nucleoside reverse transcriptase inhibitor RO91767, 8-chloro-TIBO. Fourth
International Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July,
1995. Abstract 33.<p>
<strong>41. </strong>Demeter L, Resnick L, Nawaz T, Timpone JG Jr, Batts D
and Reichman RC. Phenotypic and genotypic analysis of atevirdine (ATV)
susceptibility of HIV-1 isolates obtained from patients receiving ATV
monotherapy in a phase I clinical trial (ACTG 187): comparison to patients
receiving combination therapy with ATV and zidovudine. Third Workshop on Viral
Resistance, 1993, Gaithersburg, MD, USA.<p>
<strong>42. </strong>Balzarini J, Brouwer WG, Felauer EE, De
Clercq E and Karlsson A. Activity of various thiocarboxanilide derivatives
against wild-type and several mutant human immunodeficiency virus type 1
strains. <i>Antiviral Research</i> 1995; <strong> 27</strong>:219-236.<p>
<strong>43. </strong>Buckheit RW Jr., Snow JH, Gliakas-Boltz V, Kinjerski TL, Russell JD, Rallansch LA,
Brouwer WG, Yang SS.  Highly potent oxathiin carboxanilide derivatives with efficacy
against NNRTI resistant isolates.  <i>Antimicrob Agents Chemother </strong>1997;
<strong>41</strong>(4):831-837.<p>
<strong>44. </strong>Zhang H, Vrang L,
Backbro K, Lindz P, Sahlberg C, Unge T and Oberg B. Inhibition of human
immunodeficiency virus type 1 wild-type and mutant reverse transcriptase by
the phenyl ethyl thiozolyl thiourea derivatives trovirdine and MSG-127.
<i>Antiviral Research</i> 1995; <strong> 28</strong>:331-342.<p>
<strong>45. </strong>Vrang L, Rydergard C, Ahgren
C, Engelhardt P, Hogberg M, Johansson NG, Kangasmetsa J, Lind P, Noreen R,
Sahlberg C, Zhou XX, Karlsson A, Lopez C, Morin Jr JM, Ternansky RJ, Bell FW,
Jordan CL, Kinnick MD, Palkowitz JA, Parrish CA, Pranc P, Vasileff RT, West SJ
and Oberg B. Comparative rates of in vitro resistance development of HIV-1 to
non-nucleoside analog RT inhibitors. <i>Antiviral Research</i> 1993; <strong> 20</strong>(Supplement
1):77.<p>
<strong>46. </strong>Demeter LM, Shafer RW, Para M, Morse G, Freimuth W, Merigan TC
and Reichman RC. Delavirdine (DLV) susceptibility of HIV-1 isolates obtained
from patients receiving DLV monotherapy (ACTG 260). <i>J Acquir Immune Defic
Syndrom Hum Retrovir </strong>1995; <strong>10</strong>(S11).<p>
<strong>47. </strong>Nunberg JH, Schleif WA, Boots EJ, O'Brien JA,
Quintero JC, Hoffman JM, Emini EA and Goldman ME. Viral resistance to human
immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.
<i>Journal of Virology</i> 1991; <strong> 65</strong>(9):4887-4892.<p>
<strong>48. </strong>Saag MS, Emini EA, Laskin OL,
Douglas J, Lapidus WI, Schleif WA, Whitley RJ, Hildebrand C, Byrnes VW, Kappes
JC, Anderson KW, Massari FE and Shaw GM. A short-term clinical evaluation of
L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase L-697,661
Working Group. <i>New England Journal of Medicine</i> 1993; <strong>
329</strong>(15):1065-1072.<p>
<strong>49. </strong>Staszewski S, Miller V, Kober A, Colebunders R,
Vandercam B, Delescluse J, Clumeck N, Van Wanzeele F, De Brabander M, De Cree
J, Moeremans M, Andries K, Boucher C, Stoffels P and Janssen PAJ. Evaluation
of the efficacy and tolerance of RO18893, RO89439 (loviride) and placebo in
asymptomatic HIV-1-infected patients. <i>Antiviral Therapy</i> 1996; <strong>
1</strong>:42-50.<p>
<strong>50. </strong>Seki M, Sadakata Y, Yuasa S and Baba M. Isolation and
characterization of human immunodeficiency virus type-1 mutants resistant to
the non-nucleoside reverse transcriptase inhibitor MKC-442. <i>Antiviral
Chemistry and Chemotherapy</i> 1995; <strong> 6</strong>(2):73-79.<p>
<strong>51. </strong>Borroto-Esoda K, Noel DS, Moxham CP, Furman PA.  Preliminary genotypic analysis
of HIV-1 in plasma from volunteers receiving repeated multiple doses of MKC-442. 
<i>6th International Workshop on HIV Drug Resistance, 25-28 June 1997; St. Petersburg,
USA</strong>:  Abstract 22.<p>
<strong>52. </strong>Balzarini J,
Karlsson A and De Clercq E. Human immunodeficiency virus type 1
drug-resistance patterns with different
1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. <i>Molecular
Pharmacology</i> 1993; <strong> 44</strong>(4):694-701.<p>
<strong>53. </strong>Balzarini J, Pelemans H, Esnouf R, Dunkler A, Parniak MA, Bandamme A-M, Karlsson
A, De Clercq E, Kleim J-P.  Significance of the 225 Pro(His mutation in HIV-1
reverse transcriptase.  <i>6th International Workshop on HIV Drug Resistance, 25-28
June 1997; St. Petersburg, USA</strong>:  Abstract 21.<p>
<strong>54. </strong>Kleim JP, Winkler I, Rosner M, Kirsch R, Rubsamen-Waigmann H, Paessens A and
Reiss G.  In vitro selection for different mutational patterns in the HIV-1 reverse
transcriptase using high and low selective pressure of the nonnucleoside reverse
transcriptase inhibitor HBY 097.  <i>Virology </strong>1997; <strong>231</strong>:112-118.<p>
<strong>55. </strong>Vandamme A-M. Polymerase chain reaction (PCR) as a
diagnostic tool in HIV infection. Verhandelingen van de Koninklijke Academie
voor Geneeskunde van Belgie 1994; <strong> 56</strong>(3):231-265.<p>
<strong>56. </strong>Tanaka M, Srinivas RV, Ueno T, Kavlick MF, Hui FD, Fridland A, Driscoll JS,
Mitsuya H.  In vitro induction of human immunodeficiency virus type 1 variants
resistant to 2'-b-fluoro-2',3'-dideoxyadenosine.  <i>Antimicrob Agents Chemother </strong>1997; <strong>41</strong>(6):1313-1318.<p>
<strong>57. </strong>Balzarini J,
Velazquez S, Sanfelix A, Karlsson A, Perez-Perez MJ, Camarasa MJ and De Clercq
E. Human immunodeficiency virus type-1 specific purine analogues show a
resistance spectrum that is different from that of the human immunodeficiency
virus type-1-specific non-nucleoside analogues. <i>Molecular Pharmacology</i> 1993;
<strong> 43</strong>(1):109-114.<p>
<strong>58. </strong>Balzarini J, Karlsson A, Vandamme AM, Perez-Perez
MJ, Zhang H, Vrang L, Oberg B, Backbro K, Unge T and San-Felix A. Human
immunodeficiency virus type 1 (HIV-1) strains selected for resistance against
the HIV-1-specific
[2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5'-(4'-amino-1',2'-oxathiole-2',2'-dioxide)]-§-D-pentofuranosyl
(TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside
inhibitors. <i>Proceedings of the National Academy of Sciences, USA</i> 1993; <strong>
90</strong>(15):6952-6956.<p>
<strong>59. </strong>Vandamme A-M, Schmit JC, Balzarini J, Van Laethem K,
Witvrouw M, Hermans P, Sprecher S, Martinez-Picado J, Clotet B, Peetermans W,
Desmyter J and De Clercq E. Presence of TSAO-resistant virus strains in
non-experienced patients. Fifth International Workshop on HIV Drug Resistance,
Whistler, Canada, 3-6 July, 1996. Abstract 47.<p>
<strong>60. </strong>Balzarini J, Pelemans H,
Perez-Perez MJ, San-Felix A, Camarasa MJ, De Clercq E and Karlsson A. Marked
inhibitory activity of non-nucleoside reverse transcriptase inhibitors against
human immunodeficiency virus type 1 when combined with
(-)2',3'-dideoxy-3'-thiacytidine. <i>Molecular
Pharmacology</i> 1996; <strong>49</strong>(5):882-890.<p>
<strong>61. </strong>Balzarini J, Jonckheere H, Harrison
WA, Dao DC, Anne J, De Clercq E and Karlsson A. Oxathiin carboxanilide
derivatives: a class of non-nucleoside HIV-1-specific reverse transcriptase
inhibitors (NNRTIs) that are active against mutant HIV-1 strains resistant to
other NNRTIs. <i>Antiviral Chemistry and Chemotherapy</i> 1995; <strong> 6</strong>:169-178.<p>
<strong>62. </strong>Schmit JC, Vanderlinden I, Ruiz L, Clotet B, Hermans P, Sprecher S, Arendt
V, Peetermans W, Harrer T, Vaira D, Desmyter J, De Clercq E and Vandamme AM.
Prevalence of multi-drug resistance to dideoxynucleoside (ddN) analogues in
patients on ddN combination therapy. Fifth International Workshop on HIV Drug
Resistance, Whistler, Canada, 3-6 July, 1996. Abstract 39.<p>
<strong>63. </strong>Vandamme A-M, Debyser Z, Pauwels R, De Vreese K, Goubau P, Youle M, Gazzard 
B, Stoffels PA, Cauwenbergh GF, Anne J, Andries K, Janssen PAJ, Desmyter J and
De Clercq E. Characterization of HIV-1 strains isolated from patients treated
with TIBO R82913. <i>AIDS Research and Human Retroviruses</i> 1994; <strong>
10</strong>(1):39-46.<p>
<strong>64. </strong>de Bethune M-P, Pauwels R, Andries K, Vandamme AM,
Peeters M, Colebunders R, Stoffels P, De Clercq E and Desmyter J. AZT
resistance reversal by the non-nucleoside reverse transcriptase inhibitor
Ï-APA R18893 in a symptomatic HIV-infected individual. Second HIV
Drug Resistance Workshop, Noordwijk, The Netherlands, 3-5 June, 1993.
Abstract.<p>
<strong>65. </strong>Maass G, Immendoerfer U, Koenig B, Leser U, Mueller B, Goody R
and Pfaff E. Viral resistance to the thiazolo-iso-indolinones, a new class of
nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse
transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> 1993; <strong>
37</strong>(12):2612-2617.<p>
<strong>66. </strong>Nguyen MH, Schinazi RF, Shi C, Goudgaon NM, McKenna
PM and Mellors JW. Resistance of human immunodeficiency virus type 1 to
acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines. <i>Antimicrobial Agents
and Chemotherapy</i> 1994; <strong> 38</strong>(10):2409-2414.<p>
<strong>67. </strong>Staszewski S, Miller V,
Rehmet S, Stark T, De Cree J, De Brabander M, Peeters M, Andries K, Moeremans
M, De Raeymaeker M, Pearce G, Van Den Broeck RM, Verbiest W and Stoffels P.
Virological and immunological analysis of a triple combination pilot study
with loviride, lamivudine and zidovudine in HIV-1-infected patients. <i>AIDS</i>
1996; <strong> 10</strong>(5):F1-F7.<p>
<strong>68. </strong>Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S and Griffin J.
Human immunodeficiency virus type 1 mutants resistant to nonnucleoside
inhibitors of reverse transcriptase arise in tissue culture. <i>Proceedings of
the National Academy of Sciences, USA</i> 1991; <strong> 88</strong>(24):11241-11245.<p>
<strong>69. </strong>Mellors JW, Dutchman GE, Im GJ, Tramontano E,
Winkler SR and Cheng YC. In vitro selection and molecular characterization of
human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of
reverse transcriptase. <i>Molecular Pharmacology</i> 1992; <strong> 41</strong>(3):446-451.<p>
<strong>70. </strong>Buckheit RW Jr,
Fliakas-Boltz V, Yeagy-Bargo S, Weislow O, Mayers DL, Boyer PL, Hughes SH, Pan
BC, Chu SH and Bader JP. Resistance to
1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by
mutations at multiple sites in the HIV-1 reverse transcriptase. <i>Virology</i> 1995;
<strong> 210</strong>(1):186-193.<p>
<strong>71. </strong>Kinjerski TL, Pallansch LA and Buckheit RW Jr. Isolation and
characterization of HIV-1 isolates resistant to oxathiin carboxanilide
derivatives: Evaluation of variables in the selection process. <i>Antiviral
Chemistry and Chemotherapy</i> 1996; (in press).<p>
<strong>72. </strong>Yang SS, Pattabiraman N,
Gussio R, Pallansch L, Buckheit RW Jr and Bader JP. Cross-resistance analysis
and molecular modelling of non-nucleoside reverse transcriptase inhibitors
targeting drug-resistance Leukaemia 1996; (in press).<p>
<strong>73. </strong>Hara H, Fujihashi T, Sakata T, Kaji A, Kaji H.  Tetrahydronaphthalene lignan
compounds as potent anti-HIV type 1 agents.  <i>AIDS Research Human Retroviruses </strong>
1997; <strong>13</strong>(8):695-705.<p>
<strong>74. </strong>Balzarini J, Karlsson A, Sardana VV, Emini EA,
Camarasa MJ and De Clercq E. Human immunodeficiency virus 1 (HIV-1)-specific
reverse transcriptase (RT) inhibitors may suppress the replication of specific
drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant
(Y181C to C181I)RT HIV-1 mutants. <i>Proceedings of the National Academy of
Sciences, USA</i> 1994; <strong> 91</strong>(14):6599-6603.<p>
<strong>75. </strong>Shaw G, Wei X, Johnson V,
Taylor M, Decker J, Kilby M, Lifson J, Hahn B and Saag M. Nucleotide sequence
analysis of HIV-1 RNA and DNA from plasma and PBMCs of patients treated with
ZDV, ddI and nevirapine: rapid turnover and resistance development in vivo.
Third International Workshop on HIV Drug Resistance, Kauai, Hawaii, USA, 2-5
August, 1994. Abstract 71.<p>
<strong>76. </strong>Schinazi RF, Lloyd RM Jr, Nguyen M-H, Cannon
DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ and Mellors JW.
Characterization of human immunodeficiency viruses resistant to
oxathiolane-cytosine nucleosides. <i>Antimicrobial Agents and Chemotherapy</i> 1993;
<strong> 37</strong>(4):875-881.<p>
<strong>77. </strong>Tisdale M, Kemp SD, Parry NR and Larder BA.
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to
3'-thiacytidine inhibitors due to a mutation in the YMDD region of
reverse transcriptase. <i>Proceedings of the National Academy of Sciences, USA</i>
1993; <strong> 90</strong>:5653-5656.<p>
<strong>78. </strong>Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N,
Boucher C and Wainberg MA. The same mutation that encodes low-level human
immunodeficiency virus type 1 resistance to
2',3'-dideoxyinosine and
2',3'-dideoxycytidine confers high-level resistance to the
(-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
<i>Antimicrobial Agents and Chemotherapy</i> 1993; <strong> 37</strong>(6):1390-1392.<p>
<strong>79. </strong>Larder BA, Kemp SD and
Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of
AZT-3TC combination therapy. <i>Science</i> 1995; <strong> 269</strong>:696-699.<p>
<strong>80. </strong>Keulen W, van Wijk A, Boucher C and Berkhout B. Initial appearance of
184lle variant in 3TC-treated patients can be explained by the mutation bias
of the HIV-1 RT enzyme. Fifth International Workshop on HIV Drug Resistance,
Whistler, Canada, 3-6 July, 1996. Abstract 95.<p>
<strong>81. </strong>Gu Z, Gao
H, Li X, Parniak MA and Wainberg MA. Novel mutation in the human
immunodeficiency virus type 1 reverse transcriptase gene that encodes
cross-resistance to 2',3'-dideoxyinosine and
2',3'-dideoxycytidine. <i>Journal of Virology</i> 1992; <strong>
66</strong>(12):7128-7135. <p>
<strong>82. </strong>Schinazi RF, Lloyd RM Jr, McMillan A, Gosselin G,
Imbach JL and Sommadossi J-P. Development of HIV-1 and SIV resistant to
§-L-2',3'-dideoxycytidine analogues. Fourth
International Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July,
1995. Abstract 10.<p>
<strong>83. </strong>Moeremans M, De Raeymaeker M, Van den Broeck R,
Stoffels P and Andries K. Genotypic analysis of HIV-1 isolates from patients
receiving loviride alone or in combination with nucleoside reverse
transcriptase inhibitor. Fourth International Workshop on HIV Drug Resistance,
Sardinia, Italy, 6-9 July, 1995. Abstract 34.<p>
<strong>84. </strong>Olmsted RA, Slade DE, Kopta LA, Poppe SM, Poel TJ, Newport SW, Rank KB, Biles C,
Morge RA, Deuweke TJ, Yagi Y, Romero DL, Thomas RC, Sharma SK, Tarpley WG. 
(Alkylamino)piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum
nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human
immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of
HIV-1\sub{IIIB</strong> with reduced replication phenotypes.  <i>Journal of Virology </strong>1996;
<strong>70</strong>(6):3698-3705.<p>
<strong>85. </strong>Kleim JP, Bender R, Kirsch R,
Meichsner C, Paessens A, Rosner M, Rubsamen-Waigmann H, Kaiser R, Wichers M,
Schneweis KE, Winkler I and Riess G. Preclinical evaluation of HBY 097, a new
nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus
type 1 replication. <i>Antimicrobial Agents and Chemotherapy</i> 1995; <strong>
39</strong>(10):2253-2257.<p>
<strong>86. </strong>Kleim J-P, Bender R, Billhardt UM, Meichsner C,
Riess G, Rosner M, Winkler I and Paessens A. Activity of a novel quinoxaline
derivative against human immunodeficiency virus type 1 reverse transcriptase
and viral replication. <i>Antimicrobial Agents and Chemotherapy</i> 1993; <strong>
37</strong>(8):1659-1664.<p>
<strong>87. </strong>Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW, Larder BA.  A novel
polymorphism at codon 333 of human immunodeficiency virus type 1 reverse
transcriptase can facilitate dual resistancte to AZT and 3TC.  <i>J Virol
</strong>1998;  In Press.<p>
<strong>88. </strong>Gurusinghe AD, Land SA, Birch C, McGavin C, Hooker
DJ, Tachedjian G, Doherty R and Deacon NJ. Reverse transcriptase mutations in
sequential HIV-1 isolates in a patient with AIDS. <i>Journal of Medical Virology</i>
1995; <strong> 46</strong>(3):238-243.<p>
<strong>89. </strong>Harrigan PR, Kingborn I, Bloor S, Kemp SD, Najera I, Kohli A, and Larder
BA. Significance of amino acid variation at human immunodeficiency virus type
1 reverse transcriptase residue 210 for zidovudine susceptibility. <i>Journal of
Virology</i> 1996; <strong> 70</strong>(9): 5930-5934.<p>
<strong>90. </strong>Hooker DJ, Tachedjian G, Solomon AE, Gurusinghe AD, Land S, Anderson JL, Roy BM,
Arnold E, Deacon NJ.  An in vivo mutation from leucine to tryptophan at posiition
210 in human immunodeficiency virus type 1 reverse transcriptase contributes to
high-level resistance to 3'-azido-3'-deoxythymidine.  <i>Journal
of Virology </strong>1996; <strong>71</strong>(11):8010-8018.<p>
<strong>91. </strong>Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C, Rimland D,
Schinazi RF, Rossau R.  Line probe assay for rapid detection of drug-selected
mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. 
<i>Antimicrob Agents Chemother </strong> 1997; <strong>41</strong>(2):284-291.<p>
<strong>92. </strong>Slade DE, Vavro CL, Stapelton JT, Swack N and
St Clair MH. A cysteine at codon 215 of HIV RT confers resistance to ddC.
Second HIV Drug Resistance Workshop, Noordwijk, The Netherlands, 3-5 June,
1993. Abstract.<p>
<strong>93. </strong>Dueweke TJ, Pushkarskaya T, Poppe SM, Swaney SM, Zhao Q,
Chen SY, Stevenson M and Tarpley WG. A mutation in reverse transcriptase of
bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that
confers increased sensitivity to other nonnucleoside inhibitors. <i>Proceedings
of the National Academy of Sciences, USA</i> 1993; <strong> 90</strong>(10):4713-4717.<p>
<strong>94. </strong>Ho DD, Toyoshima T, Mo H, Kempf DJ, Norbeck D, Chen CM, Wideburg NE, Burt
SK, Erickson JW and Singh MK. Characterization of human immunodeficiency virus
type 1 variants with increased resistance to a C2-symmetric protease
inhibitor. <i>Journal of Virology</i> 1994; <strong> 68</strong>(3):2016-2020.<p>
<strong>95. </strong>Tisdale M,
Myers R, Parry NR, Oliver N, Machera B and Blair E. Comprehensive analysis of
HIV-1 variants individually selected for resistance to six HIV protease
inhibitors. Third International Workshop on HIV Drug Resistance, Kauai,
Hawaii, USA, 2-5 August, 1994. Abstract 14.<p>
<strong>96. </strong>Kaplan AH, Michael SF,
Wehbie RS, Knigge MF, Paul DA, Everitt L, Kempf DJ, Norbeck DW, Erickson JW
and Swanstrom R. Selection of multiple human immunodeficiency virus type 1
variants that encode viral proteases with decreased sensitivity to an
inhibitor of the viral protease. <i>Proceedings of the National Academy of
Sciences, USA</i> 1994; <strong> 91</strong>:5597-5601.<p>
<strong>97. </strong>Otto MJ, Reid CD, King RW,
Garber S, Baker DB, Anton E and Winslow DL. Exposure of chronically infected
PBMCs to DMP 450 can completely suppress virus replication or select resistant
variants depending upon the dose of compound. Second National Conference on
Human Retroviruses and Related Infections, Washington, DC, USA, 29 January-2
February, 1995. Abstract 464.<p>
<strong>98. </strong>Winslow DL, Garber S, Reid C, Anton E and
Otto MJ. DMP 450, a new cyclic urea inhibitor of HIV protease with potent in
vitro antiviral activity. Eighth International Conference on Antiviral
Research, Santa Fe, NM, USA, 23-28 April, 1995. Abstract 22.<p>
<strong>99. </strong>Partaledis
JA, Yamaguchi K and Byrn RA. In vitro selection and characterization of HIV-1
viral isolates with reduced sensitivity to inhibitors of HIV protease. Third
International Workshop on HIV Drug Resistance, Kauai, Hawaii, USA, 2-5
August, 1994. Abstract 8.<p>
<strong>100. </strong>Tisdale M, Myers R, Najera I, Kohli A, Kemp S
and Larder BA. Analysis of resistance interactions with 141W94 (VX-478) and
other HIV-1 protease inhibitors. Fifth International Workshop on HIV Drug
Resistance, Whistler, Canada, 3-6 July, 1996. Abstract 27.<p>
<strong>101. </strong>King RW,
Garber S, Winslow DL, Reid C, Bacheler LT, Anton E and Otto MJ. Multiple
mutations in the human immunodeficiency virus protease gene are responsible
for decreased susceptibility to protease inhibitors. <i>Antiviral Chemistry and
Chemotherapy</i> 1995; <strong> 6</strong>(2):80-88.<p>
<strong>102. </strong>Potts KE, Smidt ML, Stallings WC,
Clare M, Pillay D, Richman DD and Bryant ML. In vitro selection and
characterization of human immunodeficiency virus type 1 (HIV-1) variants with
decreased sensitivity to hydroxyethylurea isostere containing protease
inhibitors. Third International Workshop on HIV Drug Resistance, Kauai,
Hawaii, USA, 2-5 August, 1994. Abstract 4.<p>
<strong>103. </strong>Pillay D, Smidt ML, Potts
KE, Bryant ML and Richman DD. In vitro selection of protease inhibitors
resistant human immunodeficiency virus type 1 (HIV-1) strains. 34th
Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL,
USA, 2-5 October, 1996. Abstract 7.<p>
<strong>104. </strong>Smidt ML, Potts KE, Tucker SP, Blystone L, Stiebel TR Jr, Stallings WC, McDonald
JJ, Pillay D, Richman DD, Bryant ML.  A mutation in human immundeficiency virus type
1 protease at position 88, located outside the active site, confers resistance to
the hydroxyethylurea inhibitor SC-55389A.  <i>Antimicrob Agents Chemother </strong>1997;
<strong>41</strong>(3):515-522.<p>
<strong>105. </strong>Condra JH, Holder DJ, Schleif WA,
Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes
A, Robbins HL, Roth E, Shivaprakash M, Yang T, Chodakewitz JA, Deutsch PJ,
Leavitt RY, Massari FE, Mellors JW, Squires KE, Steigbigel RT, Teppler H and
Emini EA. Genetic correlates of in vivo viral resistance to the HIV-1 protease
indinavir. <i>Journal of Virology</i> 1996; 70(12): 8270-8276.<p>
<strong>106. </strong>Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D.  Impaired
fitness of human immunodeficiency virus type 1 variants with high-level resistance
to protease inhibitors.  <i>Journal of Virology </strong>1997; <strong>71</strong>(2):1089-1096.<p>
<strong>107. </strong>Schapiro JM, Winters
MA, Vierra M, Jacobsen H, Mous J and Merigan TC. Resistance mutations in
patients receiving saquinavir: simultaneous appearance in lymph nodes,
peripheral blood mononuclears (PBM) and plasma. Fifth International Workshop
on HIV Drug Resistance, Whistler, Canada, 3-6 July, 1996. Abstract 28.<p>
<strong>108. </strong>Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo
HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman R, Ho DD,
Boucher CAB, Leonard JM, Norbeck DW and Kempf DJ. Ordered accumulation for
mutation in HIV protease confers resistance to ritonavir. <i>Nature Medicine</i>
1996; <strong> 2</strong>(7):760-766.<p>
<strong>109. </strong>Doyon I, Croteau G, Thibeault D,
Poulin F, Pilocle L and Lamarre D. Second locus involved in human
immunodeficiency virus type 1 resistance to protease inhibitors. <i>Journal of
Virology</i> 1996; <strong> 70</strong>:3763-3769.<p>
<strong>110. </strong>Patick AK, Mo H, Markowitz M,
Appelt K, Wu B, Musick L, Kalish V, Kaldor S, Reich S, Ho D and Webber S.
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor
of human immunodeficiency virus protease. <i>Antimicrobial Agents and
Chemotherapy</i> 1996; <strong> 40</strong>(2):292-297; <strong> 40</strong>(6):1575 (erratum).<p>
<strong>111. </strong>Patick AK, Kuritzkes D, Johnson VA, Shugarts D, Bakhtiari M, Potts KE,
Farnsworth A, Anderson R, Koel JL, Hazelwood JD, Nail CD, Duran M, Markowitz M, Ho
D, Richman D.  Genotypic and phenotypic analyses of HIV-1 variants isolated from
patients treated with nelfinavir and other HIV-1 protease inhibitors.  <i>6th
International Workshop on HIV Drug Resistance, 25-28 June 1997; St. Petersburg,
USA</strong>:  Abstract 18.<p>
<strong>112. </strong>Lamarre D, Croteau G, Pilote L, Rousseau P and Doyon
L. Molecular characterization of HIV-1 variants resistant to specific viral
protease inhibitors. Third International Workshop on HIV Drug Resistance,
Kauai, Hawaii, USA, 2-5 August, 1994. Abstract 10.<p>
<strong>113. </strong>Lamarre D, Doyon L,
Croteau G, Pilote L and Thibeault D. Molecular basis of HIV-1 resistance to
protease inhibitors Structural flexibility of the protease and second-site
compensatory mutations in cleavage sites. Fourth International Workshop on HIV
Drug Resistance, Sardinia, Italy, 6-9 July, 1995. Abstract 62.<p>
<strong>114. </strong>Gulnik
SV, Suvorov LI, Liu B, Yu B, Anderson B, Mitsuya H and Erickson JW. Kinetic
characterization and cross-resistance patterns of HIV-1 protease mutants
selected under drug pressure. <i>Biochemistry</i> 1995; <strong> 34</strong>(29):9282-9287.<p>
<strong>115. </strong>Condra JH and Schleif WA. In vivo emergence of HIV-1 variants resistant to
multiple protease inhibitors. <i>Nature</i> 1995; <strong> 374</strong>:569-571.<p>
<strong>116. </strong>Borman AM, Paulous S and Clavel F. Continued accumulation of protease
inhibitor resistance mutations in culture in the absence of the drug. Fourth
International Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July,
1995. Abstract 93.<p>
<strong>117. </strong>Jacobsen H, Brun-Vezinet F,
Duncan I, Hanggi M, Ott M, Vella S, Weber J and Mous J. Genotypic
characterization of HIV-1 from patients after prolonged treatment with
proteinase inhibitor saquinivir. Third International Workshop on HIV Drug
Resistance, Kauai, Hawaii, USA, 2-5 August, 1994. Abstract 16.<p>
<strong>118. </strong>Eberle
J, Bechowsky B, Rose D, Hauser U, Von Der Helm K, Gurtler L and Nitschki H.
Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. <i>AIDS Research
and Human Retroviruses</i> 1995; <strong> 11</strong>(6):671-676.<p>
<strong>119. </strong>Mo H, Markowitz M, Majer P, Burt SK, Gulnik SV, Suvorov LI, Erickson JW, Ho DD. 
Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel
inhibitors of HIV type 1 protease.  <i>AIDS Research and Human Retroviruses </strong>1996;
<strong>12</strong>(1):55-61.<p>
<strong>120. </strong>Vasudevachari MB, Zhang Y-M, Imamichi H, Imamich T, Falloon J, Salzman NP. 
Emergence of protease inhibitor resistance mutations in human immunodeficiency virus
type 1 isolates from patients and rapid screening procedure for their detection. 
<i>Antimicrob Agents Chemother </strong>1996; <strong>40</strong>(11):2535-2541.<p>
<strong>121. </strong>Rao BG, Dwyer MD,
Thomson JA, Baker CT, Deininger DD, Murcko MA, Tung RD, Navia MA and Kim EE.
Structural and modelling analysis of the basis of viral resistance to VX-478.
Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, 3-6
July, 1996. Abstract 22.<p>
<strong>122. </strong>Patick AK, Rose R, Greytok J, Bechtol CM,
Hermsmeier MA, Chen PT, Barrish JC, Zahler R, Colonno RJ and Lin PF.
Characterization of a human immunodeficiency virus type 1 variant with reduced
sensitivity to an aminodiol protease inhibitor. <i>Journal of Virology</i> 1995; <strong>
69</strong>(4):2148-2152.<p>
<strong>123. </strong>Rose B, Greytok J, Bechtold C, Alam M, Terry B, Gong
YF, DeVore K, Patrick A, Colono R and Lin PF. Combination therapy with two
protease inhibitors as an approach to antiviral therapy. Third International
Workshop on HIV Drug Resistance, Kauai, Hawaii, USA, 2-5 August, 1994.
Abstract 17.<p>
<strong>124. </strong>Dulioust A, Paulous S, Guillemot L, Boue F, Galanaud P, Clavel F.  Selection of
saquinavir-resistant mutants by indinavir following a switch from saquinavir.  <i>6th
International Workshop on HIV Drug Resistance, 25-38 June 1997; St. Petersburg,
USA</strong>:  Abstract 16.<p>
<strong>125. </strong>Swanstrom R, Smith T, Petit S, Irlbeck D, Shao W, Wehbie
R, Sawhney R, Everitt L and Erickson I. Multiple sequence changes within HIV-1
protease confer reduced sensitivity to a symmetric protease inhibitor. Third
International Workshop on HIV Drug Resistance, Kauai, Hawaii, USA, 2-5
August, 1994. Abstract 6.<p>
<strong>126. </strong>Otto MJ, Garber S, Winslow DL, Reid CD, Aldrich P,
Jadhav PK, Patterson CE, Hodge CN and Cheng YS. In vitro isolation and
identification of human immunodeficiency virus (HIV) variants with reduced
sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. <i>Proceedings
of the National Academy of Sciences, USA</i> 1993; <strong> 90</strong>(16):7543-7.<p>
<strong>127. </strong>Winters MA, Schapiro JM, Lawrence J, Merigan TC.  Genotypic and phenotypic
analysis of the protease gene in HIV-1-infected patients that failed long-term
saquinavir therapy and switched to other protease inhibitors.  <i>6th International
Workshop on HIV Drug Resistance, 25-28 June 1997; St. Petersburg, USA</strong>:  Abstract
17.<p>
<strong>128. </strong>Eastman PS, Duncan IB, Gee C, Race E.  Acquisition of genotypic mutations
associated with reduced susceptibility to protease inhibitors during saquinavir
monotherapy.  <i>6th International Workshop on HIV Drug Resistance, 25-28 June
1997; St. Petersburg, USA</strong>:  Abstract 30.<p>
<strong>129. </strong>Schapiro JM, Winters M, Lawrence J, Norris J, Merigan TC.  Clinical and
genotypic cross-resistance between the protease inhibitors saquinavir and
indinavir.  <i>6th International Workshop on HIV Drug Resistance, 25-28 June
1997; St. Petersburg, USA</strong>:  Abstract 87<p>
<strong>130. </strong>Shao W, Smith T and Swanstrom R. Selection and analysis of HIV-1 variants
with increased resistance to SKF108842 and SKF108922, two protease inhibitors.
Fourth International Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9
July, 1995. Abstract 65.<p>
<strong>131. </strong>el-Farrash MA, Kuroda MJ, Kitazaki T, Masuda
T, Kato K, Hatanaka M and Harada S. Generation and characterization of a human
immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease
inhibitor. <i>Journal of Virology</i> 1994; <strong> 68</strong>(1):233-9.<p>
<strong>132. </strong>Labrosse B, Pleskoff O, Sol N, Jones C, Henin Y, Alizon M.  Antiviral and
resistance studies of RPR103611, an inhibitor of HIV replication.  <i>6th
International Workshop on HIV Drug Resistance, 25-28 June 1997; St. Petersburg,
USA</strong>:  Abstract 33.<p>
<strong>133. </strong>Este JA, Schols D, De Vreese K, Van Laethem K, Vandamme AM,
Desmyter J and De Clercq E. Development of resistance of human
immunodeficiency virus type 1 to dextran sulfate associated with the emergence
of specific mutations in the envelope gp120 glycoprotein. Molecular Pharmacology 1997; <strong> 52</strong>(1):  98-104.<p>
<strong>134. </strong>Este JA, Van
Laethem K, Vandamme AM, Desmyter J and De Clercq E. Resistant phenotype of
human immunodeficiency virus type 1 to dextran sulfate is conferred by
specific amino acid substitutions in the gp120 molecule. Fifth International
Workshop on HIV Drug Resistance, Whistler, Canada, 3-6 July, 1996. Abstract
80.<p>
<strong>135. </strong>De Vreese K, Reymen D, Griffin P, Steinkasserer A,
Werner G, Bridger GJ, Este J, James W, Henson GW, Desmyter J, Anne J and De
Clercq E. The bicyclams, a new class of potent human immunodeficiency virus
inhibitors, block viral entry after binding. <i>Antiviral Research</i> 1996; <strong>
29</strong>:209-219.<p>
<strong>136. </strong>De Vreese K, Kofler-Mongold V, Leutgeb C, Weber V,
Vermeire K, Schacht S, Anne J, De Clercq E, Datema R and Werner G. The
molecular target of bicyclams, potent inhibitors of human immunodeficiency
virus replication. <i>Journal of Virology</i> 1996; <strong> 70</strong>(2):689-696.<p>
<strong>137. </strong>Lin
P, Samanta H, Bechtold CM, Deminie CA, Patick AK, Alam M, Riccardi K, Rose RE,
White RJ and Colonno RJ. Characterization of siamycin 1, a human
immunodeficiency virus fusion inhibitor. <i>Antimicrobial Agents and Chemotherapy</i>
1995; <strong> 40</strong>:133-138.<p>
<strong>138. </strong>Van Rompay KKA, Cherrington JM, Marthas ML, Barardi CJ, Mulato AS, Spinner
A, Tarara RP, Canfield DR, Telm S, Bischofberger N, Pedersen NC.  PMPA therapy
of established SIV infection of infant rhesus macaques.  <i>Antimicrob Agents
Chemother </strong>1996; <strong>40</strong>:2586-2591.<p>
<strong>139. </strong>Cherrington JM, Van Rompay KKA, Mulato AS, Marthas ML, Berardi CJ, Telm S,
Bischofberger N, Pedersen NC.  Phenotypic and genotypic characterization of
simian immunodeficiency viruses (SIV) with reduced susceptibility to PMPA
isolated after PMPA therapy.  <i>Fifth International Workshop on HIV Drug
Resistance, 1996, Whistler, Canada</strong>:  Abstract 75.<p>
<strong>140. </strong>Van Rompay K, Cherrington J, Marthas M, Agatep E, Dehqanzada Z, Lamy P,
Berardi C, Bischofberger N, Pedersen N.  Therapeutic efficacy of PMPA treatment
for infant macaques infected with PMPA-resistant simian immunodeficiency virus. 
<i>6th International Workshop on HIV Drug Resistance, 25-28 June 1997; St.
Petersburgh, USA</strong>:  Abstract 117.<p>
<strong>141. </strong>Van Rompey KKA, Breenier JL, Marthas ML, Otsyula MG, Tarar RP, Miller CJ,
Pedersen NC.  A zidovudine resistant simian immunodefiency virus mutant with a
Q151M mutation in reverse transcriptase causes AIDS in newborn macaques.  <i>Antimicrob Agents Chemother </strong>1997; <strong>41</strong>:278-283.<p>
<strong>142. </strong>Medlin HK, Zhu Y, Remington KM, Phillips TR, North TW.  Selection and
characterization of a mutant of feline immunodeficiency virus resistant to
2',3'-dideoxycytidine.  <i>Antimicrob Agents Chemother </strong>1996;
<strong>40</strong>:953-957.<p>
<strong>143. </strong>Zhu Y-Q, Remington KM, North TW.  Mutants of feline immunodeficiency
resistance to
2',3'-dideoxy-2',3'-didehydrothymidine.  <i>Antimicrob Agents Chemother </strong>1996; <strong>40</strong>:1983-1987.<p>
<strong>144. </strong>Smith RA, Reminton KM, Lloyd RM Jr., Schinazi RF, North TW.  A novel point
mutation at position 156 of reverse transcriptase from feline immunodeficiency
virus confers resistance to the combination of
(-)-§-L-2',3'-dideoxy-3'-thiacytidine and
3'-azido-3'-deoxythymidine.  <i>J Virol </strong>1997; submitted for
publication.<p>
<strong>145. </strong>Smith R, Remington K, Lloyd R, Schinazi R, North T.  Mutants of feline
immunodeficiency virus resistant to FTC and 3TC.  <i>Third International Feline
Retrovirus Research Symposium, 1996, Ft. Collins, CO</strong>:  Abstract 41.<p>
<strong>146. </strong>Smith RA, Remington K, Lloyd RM Jr, Schinazi RF, North TW.  A novel met to
thr mutation in the YMDD motif of reverse transcriptase from feline
immunodeficiency virus confers resistance to oxathiolane nucleosides.  <i>J
Virol </strong>1997; <strong>71</strong>:2357-2362.<p>

</td></tr>
	    <tr><td><table bgcolor="white" width="100%" align="center" cellpadding="0" cellspacing="0" border="0">
  <tr><td>&nbsp;</td></tr>
  <tr><td colspan=2 align=center>Questions or comments? Contact us at <a href="mailto:seq-info@t10.lanl.gov"><font color="#8f8fbd" face="helvetica">seq-info@t10.lanl.gov</font></a></td></tr>
  <tr><td>&nbsp;</td></tr>
</table>



</td></tr>
	  </table>  
        </td>
      </tr>	
    </table>
  </body>
</html>      

<!-- no autohandlers upstream -->


